ClinicalTrials.gg
CompletedNCT01272999Updated May 23, 2023Results posted

Impact of Prevnar 13 on Ear Infections in Children

An observational study in Acute Otitis Media and Mastoiditis, sponsored by Pfizer. Completed at 8 sites in United States. Open to participants aged 0 Years and older. Per ClinicalTrials.gov, last updated 2023-05-23.

Sponsored by Pfizer · Observational

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Case-only
Time perspective
Prospective
Enrollment
391
Ages
0 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 110 studies in Otitis Media with a site in United States — 12 open to participants now, 23 under way, none of them phase 3. Otitis Media · United States.

Enrollment
8th of 23
391 · median 200
Started
2010
with 7 others
Observational
23 of 110
3 open now
Registered
37th of 110
by date
Lead sponsor
4 of 110
Pfizer

Among the 110 studies in Otitis Media with a site in United States, this one is the 8th largest by enrollment of the 23 observational ones that give a count, is one of 8 that started in 2010, is one of 23 observational ones, and was the 37th registered.

Otitis Media

241 studies on the registry are indexed under Otitis Media; 32 are open to participants now.

Browse Otitis Media studies →

Open to participants now

12 of the 110 studies in Otitis Media with a site in United States are open now. Recruiting first, the newest first:

7 more — sign in →

All 12 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 20 Otitis Media studies recruiting now, 5 (25%) set no upper age limit and 15 (75%) stop at 75 or younger; 19 take children under 18; 4 take healthy volunteers.

This study: 0 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 110 studies in Otitis Media with a site in United States, or all of them as a file.
02

Study summary

Prevnar (7 valent pneumococcal conjugate vaccine [7vPnC]) has been shown to be effective against ear infections in children. Prevnar 13 is a new vaccine that is similar to Prevnar. It is expected that the effectiveness of Prevnar 13 against ear infections in children will be similar to that observed following Prevnar. Pfizer has committed to conduct a postmarketing study of the impact of Prevnar 13 in reducing ear infections among children.

03

Conditions studied

  • Acute Otitis Media
  • Mastoiditis

Browse trials for

Keywords

  • Acute otitis media
  • Prevnar 13
  • Streptococcus pneumoniae
04

Who can participate

Ages eligible
0 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Children aged 6 weeks to 18 years

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Case eligibility should be based on microbiologic data and should be reviewed and documented by an appropriately qualified member of the investigator's study team before cases are included in the study database.
  • S pneumoniae identified from middle ear fluid or mastoiditis sample.
  • Specimen obtained from children aged up to 18 years.

Exclusion criteria

Exclusion Criteria:

  • As this is an observational, laboratory based database study, there are no exclusion criteria
05

Study design

Observational model
Case-only
Time perspective
Prospective
Enrollment
391 participants (actual)
Biospecimen retention
None retained

Groups and cohorts

  • 1

    Otitis media cases

    Other: No intervention

Interventions

  • OtherNo intervention

    Non interventional

06

What researchers measure

Primary outcomes

  1. Percentage of Streptococcus Pneumoniae Serotype Isolates From Middle Ear Fluid (MEF) Sample at Surveillance Year 1

    The distribution of S pneumoniae serotypes isolated from MEF samples from children in the target population for vaccination over the surveillance year 1 were presented. The percentage of isolates of S pneumoniae serotypes included in Prevnar 13 (3, 7F, 19A, 19F) and not included in Prevnar 13 (6C, 7C, 9N, 10, 11, 12, 12F, 13, 15A, 15B, 15C, 15F, 16, 17, 20, 21, 22F, 23A, 23B, 31, 33A, 33F, 34, 35B, 35F, 38) along with total (both included and not included), clumps and missing or non-viable were computed along with exact 2-sided 95 percent (%) confidence interval (CI) based on the observed proportion of isolates. Missing or non-viable included isolates that were either not sent from an external laboratory, were non-viable or lost on culture prior to sending, or were non-viable on receipt in the central laboratory.'Number of isolates analyzed' signifies total number of isolates that were evaluable for this outcome measure (OM).

    Time frame: Surveillance Year 1

  2. Percentage of Streptococcus Pneumoniae Serotype Isolates From Middle Ear Fluid (MEF) Sample at Surveillance Year 2

    The distribution of S pneumoniae serotypes isolated from MEF samples from children in the target population for vaccination over the surveillance year 2 were presented. The percentage of isolates of S pneumoniae serotypes included in Prevnar 13 (3, 7F, 19A, 19F) and not included in Prevnar 13 (6C, 7C, 9N, 10, 11, 12, 12F, 13, 15A, 15B, 15C, 15F, 16, 17, 20, 21, 22F, 23A, 23B, 31, 33A, 33F, 34, 35B, 35F, 38) along with total (both included and not included), clumps and missing or non-viable were computed along with exact 2-sided 95% CI based on the observed proportion of isolates. Missing or non-viable included isolates that were either not sent from an external laboratory, were non-viable or lost on culture prior to sending, or were non-viable on receipt in the central laboratory.'Number of isolates analyzed' signifies total number of isolates that were evaluable for this OM.

    Time frame: Surveillance Year 2

  3. Percentage of Streptococcus Pneumoniae Serotype Isolates From Middle Ear Fluid (MEF) Sample at Surveillance Year 3

    The distribution of S pneumoniae serotypes isolated from MEF samples from children in the target population for vaccination over the surveillance year 3 were presented. The percentage of isolates of S pneumoniae serotypes included in Prevnar 13 (3, 7F, 19A, 19F) and not included in Prevnar 13 (6C, 7C, 9N, 10, 11, 12, 12F, 13, 15A, 15B, 15C, 15F, 16, 17, 20, 21, 22F, 23A, 23B, 31, 33A, 33F, 34, 35B, 35F, 38) along with total (both included and not included), clumps and missing or non-viable were computed along with exact 2-sided 95% CI based on the observed proportion of isolates. Missing or non-viable included isolates that were either not sent from an external laboratory, were non-viable or lost on culture prior to sending, or were non-viable on receipt in the central laboratory.'Number of isolates analyzed' signifies total number of isolates that were evaluable for this OM.

    Time frame: Surveillance Year 3

  4. Percentage of Streptococcus Pneumoniae Serotype Isolates From Mastoiditis Sample at Surveillance Year 1

    The distribution of S pneumoniae serotypes isolated from mastoiditis samples from children in the target population for vaccination over the surveillance year 1 were presented. The percentage of isolates of S pneumoniae serotypes included in Prevnar 13 (1, 3, 7F, 14, 19A, 19F) and not included in Prevnar 13 (6C, 12, 15A, 15B, 15F, 21, 22F, 23A, 33F, 35B, 38) along with total (both included and not included in Prevnar 13 ), clumps and missing or non-viable were computed along with exact 2-sided 95% CI based on the observed proportion of isolates. Missing or non-viable included isolates that were either not sent from an external laboratory, were non-viable or lost on culture prior to sending, or were non-viable on receipt in the central laboratory.'Number of isolates analyzed' signifies total number of isolates that were evaluable for this OM.

    Time frame: Surveillance Year 1

  5. Percentage of Streptococcus Pneumoniae Serotype Isolates From Mastoiditis Sample at Surveillance Year 2

    The distribution of S pneumoniae serotypes isolated from mastoiditis samples from children in the target population for vaccination over the surveillance year 2 were presented. The percentage of isolates of S pneumoniae serotypes included in Prevnar 13 (1, 3, 7F, 14, 19A, 19F) and not included in Prevnar 13 (6C, 12, 15A, 15B, 15F, 21, 22F, 23A, 33F, 35B, 38) along with total (both included and not included in Prevnar 13 ), clumps and missing or non-viable were computed along with exact 2-sided 95% CI based on the observed proportion of isolates. Missing or non-viable included isolates that were either not sent from an external laboratory, were non-viable or lost on culture prior to sending, or were non-viable on receipt in the central laboratory.'Number of isolates analyzed' signifies total number of isolates that were evaluable for this OM.

    Time frame: Surveillance Year 2

  6. Percentage of Streptococcus Pneumoniae Serotype Isolates From Mastoiditis Sample at Surveillance Year 3

    The distribution of S pneumoniae serotypes isolated from mastoiditis samples from children in the target population for vaccination over the surveillance year 3 were presented. The percentage of isolates of S pneumoniae serotypes included in Prevnar 13 (1, 3, 7F, 14, 19A, 19F) and not included in Prevnar 13 (6C, 12, 15A, 15B, 15F, 21, 22F, 23A, 33F, 35B, 38) along with total (both included and not included in Prevnar 13 ), clumps and missing or non-viable were computed along with exact 2-sided 95% CI based on the observed proportion of isolates. Missing or non-viable included isolates that were either not sent from an external laboratory, were non-viable or lost on culture prior to sending, or were non-viable on receipt in the central laboratory.'Number of isolates analyzed' signifies total number of isolates that were evaluable for this OM.

    Time frame: Surveillance Year 3

Secondary outcomes

  1. Antimicrobial Susceptibility of Streptococcus Pneumoniae Isolates for Amoxicillin: Middle Ear Fluid (MEF) Population

    Antimicrobial susceptibility of S pneumoniae isolates for amoxicillin from MEF samples was categorized as resistant, susceptible or intermediate based on minimum inhibitory concentration (MIC) for each serotype at each year of the whole surveillance period. The percentage of S pneumoniae serotypes included 3, 6C, 7C, 9N, 10, 11, 12, 12F, 13, 15A, 15B, 15C, 15F, 16, 17, 19 A, 19 F, 20, 21, 22F, 23A, 23B, 31, 33A, 33F, 34, 35B, 35F, 38, clumps and missing or non-viable, which were to be computed along with exact 2-sided 95% CI based on the observed proportion of isolates. Missing or non-viable included isolates that were either not sent from an external laboratory, were non-viable or lost on culture prior to sending, or were non-viable on receipt in the central laboratory.'Number of isolates analyzed' signifies total number of isolates that were evaluable for this OM.

    Time frame: Surveillance Year 1, 2, 3

  2. Antimicrobial Susceptibility of Streptococcus Pneumoniae Isolates for Cefotaxime: Middle Ear Fluid (MEF) Population

    Antimicrobial susceptibility of S pneumoniae isolates for cefotaxime from MEF samples was categorized as resistant, susceptible or intermediate based on MIC for each serotype at each year of the whole surveillance period. The percentage of S pneumoniae serotypes included 3, 6C, 7C, 9N, 10, 11, 12, 12F, 13, 15A, 15B, 15C, 15F, 16, 17, 19 A, 19 F, 20, 21, 22F, 23A, 23B, 31, 33A, 33F, 34, 35B, 35F, 38, clumps and missing or non-viable, which were to be computed along with exact 2-sided 95% CI based on the observed proportion of isolates. Missing or non-viable included isolates that were either not sent from an external laboratory, were non-viable or lost on culture prior to sending, or were non-viable on receipt in the central laboratory.'Number of isolates analyzed' signifies total number of isolates that were evaluable for this OM.

    Time frame: Surveillance Year 1, 2, 3

  3. Antimicrobial Susceptibility of Streptococcus Pneumoniae Isolates for Ceftriaxone: Middle Ear Fluid (MEF) Population

    Antimicrobial susceptibility of S pneumoniae isolates for ceftriaxone from MEF samples was categorized as resistant, susceptible or intermediate based on MIC for each serotype at each year of the whole surveillance period. The percentage of S pneumoniae serotypes included 3, 6C, 7C, 9N, 10, 11, 12, 12F, 13, 15A, 15B, 15C, 15F, 16, 17, 19 A, 19 F, 20, 21, 22F, 23A, 23B, 31, 33A, 33F, 34, 35B, 35F, 38, clumps and missing or non-viable, which were to be computed along with exact 2-sided 95% CI based on the observed proportion of isolates. Missing or non-viable included isolates that were either not sent from an external laboratory, were non-viable or lost on culture prior to sending, or were non-viable on receipt in the central laboratory.'Number of isolates analyzed' signifies total number of isolates that were evaluable for this OM.

    Time frame: Surveillance Year 1, 2, 3

  4. Antimicrobial Susceptibility of Streptococcus Pneumoniae Isolates for Clindamycin: Middle Ear Fluid (MEF) Population

    Antimicrobial susceptibility of S pneumoniae isolates for clindamycin from MEF samples was categorized as resistant, susceptible or intermediate based on MIC for each serotype at each year of the whole surveillance period. The percentage of S pneumoniae serotypes included 3, 6C, 7C, 9N, 10, 11, 12, 12F, 13, 15A, 15B, 15C, 15F, 16, 17, 19 A, 19 F, 20, 21, 22F, 23A, 23B, 31, 33A, 33F, 34, 35B, 35F, 38, clumps and missing or non-viable, which were to be computed along with exact 2-sided 95% CI based on the observed proportion of isolates. Missing or non-viable included isolates that were either not sent from an external laboratory, were non-viable or lost on culture prior to sending, or were non-viable on receipt in the central laboratory.'Number of isolates analyzed' signifies total number of isolates that were evaluable for this OM.

    Time frame: Surveillance Year 1, 2, 3

  5. Antimicrobial Susceptibility of Streptococcus Pneumoniae Isolates for Erythromycin: Middle Ear Fluid (MEF) Population

    Antimicrobial susceptibility of S pneumoniae isolates for erythromycin from MEF samples was categorized as resistant, susceptible or intermediate based on MIC for each serotype at each year of the whole surveillance period. The percentage of S pneumoniae serotypes included 3, 6C, 7C, 9N, 10, 11, 12, 12F, 13, 15A, 15B, 15C, 15F, 16, 17, 19A, 19F, 20, 21, 22F, 23A, 23B, 31, 33A, 33F, 34, 35B, 35F, 38, clumps and missing or non-viable, which were to be computed along with exact 2-sided 95% CI based on the observed proportion of isolates. Missing or non-viable included isolates that were either not sent from an external laboratory, were non-viable or lost on culture prior to sending, or were non-viable on receipt in the central laboratory.'Number of isolates analyzed' signifies total number of isolates that were evaluable for this OM.

    Time frame: Surveillance Year 1, 2, 3

  6. Antimicrobial Susceptibility of Streptococcus Pneumoniae Isolates for Penicillin: Middle Ear Fluid (MEF) Population

    Antimicrobial susceptibility of S pneumoniae isolates for penicillin from MEF samples were summarized by providing the range of MICs for penicillin tested and the percentage of the susceptibility interpretation was categorized as resistant, susceptible or intermediate for each serotype, and for each year of the whole surveillance period. The percentage of S pneumoniae serotypes included 3, 6C, 7C, 9N, 10, 11, 12, 12F, 13, 15A, 15B, 15C, 15F, 16, 17, 19 A, 19 F, 20, 21, 22F, 23A, 23B, 31, 33A, 33F, 34, 35B, 35F, 38, clumps and missing or non-viable, which were to be computed along with exact 2-sided 95 % CI based on the observed proportion of isolates. Missing or non-viable included isolates that were either not sent from an external laboratory, were non-viable or lost on culture prior to sending, or were non-viable on receipt in the central laboratory.'Number of isolates analyzed' signifies total number of isolates that were evaluable for this OM.

    Time frame: Surveillance Year 1, 2, 3

  7. Antimicrobial Susceptibility of Streptococcus Pneumoniae Isolates for Trimethoprim/Sulfamethoxazole (TMP/S): Middle Ear Fluid (MEF) Population

    Antimicrobial susceptibility of S pneumoniae isolates for TMP/S from MEF samples was categorized as resistant, susceptible or intermediate based on MIC for each serotype at each year of the whole surveillance period. The percentage of S pneumoniae serotypes included 3, 6C, 7C, 9N, 10, 11, 12, 12F, 13, 15A, 15B, 15C, 15F, 16, 17, 19A, 19F, 20, 21, 22F, 23A, 23B, 31, 33A, 33F, 34, 35B, 35F, 38, clumps and missing or non-viable, which were to be computed along with exact 2-sided 95% CI based on the observed proportion of isolates. Missing or non-viable included isolates that were either not sent from an external laboratory, were non-viable or lost on culture prior to sending, or were non-viable on receipt in the central laboratory.'Number of isolates analyzed' signifies total number of isolates that were evaluable for this OM.

    Time frame: Surveillance Year 1, 2, 3

  8. Antimicrobial Susceptibility of Streptococcus Pneumoniae Isolates for Ceftriaxone: Mastoid Population

    Antimicrobial susceptibility of S pneumoniae isolates for ceftriaxone from mastoid samples was categorized as resistant, susceptible or intermediate based on MIC for each serotype at each year of the whole surveillance period. The percentage of S pneumoniae serotypes included 3, 12, 15A, 15B, 15F, 19A, 19F, 21, 22F, 23A, 38, which were to be computed along with exact 2-sided 95% CI based on the observed proportion of isolates. 'Number of isolates analyzed' signifies total number of isolates that were evaluable for this OM.

    Time frame: Surveillance Year 1, 2, 3

  9. Antimicrobial Susceptibility of Streptococcus Pneumoniae Isolates for Clindamycin: Mastoid Population

    Antimicrobial susceptibility of S pneumoniae isolates for clindamycin from mastoid samples was categorized as resistant, susceptible or intermediate based on MIC for each serotype at each year of the whole surveillance period. The percentage of S pneumoniae serotypes included 3, 12, 15A, 15B, 15F, 19A, 19F, 21, 22F, 23A, 38, which were to be computed along with exact 2-sided 95% CI based on the observed proportion of isolates. 'Number of isolates analyzed' signifies total number of isolates that were evaluable for this OM.

    Time frame: Surveillance Year 1, 2, 3

  10. Antimicrobial Susceptibility of Streptococcus Pneumoniae Isolates for Erythromycin: Mastoid Population

    Antimicrobial susceptibility of S pneumoniae isolates for erythromycin from mastoid samples was categorized as resistant, susceptible or intermediate based on MIC for each serotype at each year of the whole surveillance period. The percentage of S pneumoniae serotypes included 3, 12, 15A, 15B, 15F, 19A, 19F, 21, 22F, 23A, 38, which were to be computed along with exact 2-sided 95% CI based on the observed proportion of isolates. 'Number of isolates analyzed' signifies total number of isolates that were evaluable for this OM.

    Time frame: Surveillance Year 1, 2, 3

  11. Antimicrobial Susceptibility of Streptococcus Pneumoniae Isolates for Penicillin: Mastoid Population

    Antimicrobial susceptibility of S pneumoniae isolates for penicillin from mastoid samples was categorized as resistant, susceptible or intermediate based on MIC for each serotype at each year of the whole surveillance period. The percentage of S pneumoniae serotypes included 3, 12, 15A, 15B, 15F, 19A, 19F, 21, 22F, 23A, 38, which were to be computed along with exact 2-sided 95% CI based on the observed proportion of isolates. 'Number of isolates analyzed' signifies total number of isolates that were evaluable for this OM.

    Time frame: Surveillance Year 1, 2, 3

  12. Antimicrobial Susceptibility of Streptococcus Pneumoniae Isolates for Trimethoprim/Sulfamethoxazole (TMP/S): Mastoid Population

    Antimicrobial susceptibility of S pneumoniae isolates for TMP/S from mastoid samples was categorized as resistant, susceptible or intermediate based on MIC for each serotype at each year of the whole surveillance period. The percentage of S pneumoniae serotypes included 3, 12, 15A, 15B, 15F, 19A, 19F, 21, 22F, 23A, 38, which were to be computed along with exact 2-sided 95% CI based on the observed proportion of isolates. 'Number of isolates analyzed' signifies total number of isolates that were evaluable for this OM.

    Time frame: Surveillance Year 1, 2, 3

  13. Percentage of Participants With Primary Clinical Diagnosis of Otitis Media

    Percentage of participants with primary diagnosis of otitis media was computed along with exact 2-sided 95% CI based on the observed proportion of participants for each of the 3 surveillance year. Results for baseline period were analyzed for participants who received routinely recommended vaccination of 13vPnC. The cases of otitis media reported during the baseline period were captured by the Texas Children's Hospital, which was the only site that collected this information during the baseline period. Percentage of participants was calculated by dividing number of participants with at least 1 MEF sample for the specified year by total number of participants with at least 1 MEF sample for the 3 year surveillance period.

    Time frame: Baseline Year 1, 2, 3; Surveillance Year 1, 2, 3

  14. Percentage of Participants With Primary Clinical Diagnosis of Mastoiditis

    Percentage of participants with primary diagnosis of mastoiditis was computed along with exact 2-sided 95% CI based on the observed proportion of participants for each of the 3 surveillance year. Percentage of participants was calculated by dividing number of participants with at least 1 mastoid sample for the specified year by total number of participants with at least 1 mastoid sample for the 3 year surveillance period.

    Time frame: Surveillance Year 1, 2, 3

07

Results

Posted Nov 10, 2020

Participant flow

Participant flow — Overall Study
MilestoneMEF PopulationMastoid Population
Started35734
Completed35734
Not completed00

Outcome measures

PrimaryPercentage of Streptococcus Pneumoniae Serotype Isolates From Middle Ear Fluid (MEF) Sample at Surveillance Year 1

The distribution of S pneumoniae serotypes isolated from MEF samples from children in the target population for vaccination over the surveillance year 1 were presented. The percentage of isolates of S pneumoniae serotypes included in Prevnar 13 (3, 7F, 19A, 19F) and not included in Prevnar 13 (6C, 7C, 9N, 10, 11, 12, 12F, 13, 15A, 15B, 15C, 15F, 16, 17, 20, 21, 22F, 23A, 23B, 31, 33A, 33F, 34, 35B, 35F, 38) along with total (both included and not included), clumps and missing or non-viable were computed along with exact 2-sided 95 percent (%) confidence interval (CI) based on the observed proportion of isolates. Missing or non-viable included isolates that were either not sent from an external laboratory, were non-viable or lost on culture prior to sending, or were non-viable on receipt in the central laboratory.'Number of isolates analyzed' signifies total number of isolates that were evaluable for this outcome measure (OM).

Time frame:
Surveillance Year 1
Reported as:
Number · percentage of isolates
Percentage of Streptococcus Pneumoniae Serotype Isolates From Middle Ear Fluid (MEF) Sample at Surveillance Year 1
percentage of isolatesMEF Population
Serotype included in Prevnar 13:35.9 (2.6 to 11.3)
Serotype included in Prevnar 13:7F0.7 (0.0 to 4.1)
Serotype included in Prevnar 13:19A31.9 (24.1 to 40.4)
Serotype included in Prevnar 13:19F2.2 (0.5 to 6.4)
Total Serotype included in Prevnar 1340.7 (32.4 to 49.5)
Serotype not included in Prevnar 13:6C6.7 (3.1 to 12.3)
Serotype not included in Prevnar 13:7C1.5 (0.2 to 5.2)
Serotype not included in Prevnar 13:9N2.2 (0.5 to 6.4)
Serotype not included in Prevnar 13:103.7 (1.2 to 8.4)
Serotype not included in Prevnar 13:113.7 (1.2 to 8.4)
Serotype not included in Prevnar 13:120.7 (0.0 to 4.1)
Serotype not included in Prevnar 13:12F0.0 (0.0 to 2.7)
Serotype not included in Prevnar 13:130.7 (0.0 to 4.1)
Serotype not included in Prevnar 13:15A3.7 (1.2 to 8.4)
Serotype not included in Prevnar 13:15B4.4 (1.6 to 9.4)
Serotype not included in Prevnar 13:15C3.7 (1.2 to 8.4)
Serotype not included in Prevnar 13:15F0.0 (0.0 to 2.7)
Serotype not included in Prevnar 13:161.5 (0.2 to 5.2)
Serotype not included in Prevnar 13:170.0 (0.0 to 2.7)
Serotype not included in Prevnar 13:200.0 (0.0 to 2.7)
Serotype not included in Prevnar 13:213.0 (0.8 to 7.4)
Serotype not included in Prevnar 13:22F1.5 (0.2 to 5.2)
Serotype not included in Prevnar 13:23A3.7 (1.2 to 8.4)
Serotype not included in Prevnar 13:23B2.2 (0.5 to 6.4)
Serotype not included in Prevnar 13:312.2 (0.5 to 6.4)
Serotype not included in Prevnar 13:33A0.7 (0.0 to 4.1)
Serotype not included in Prevnar 13:33F3.0 (0.8 to 7.4)
Serotype not included in Prevnar 13:340.0 (0.0 to 2.7)
Serotype not included in Prevnar 13:35B6.7 (3.1 to 12.3)
Serotype not included in Prevnar 13:35F0.0 (0.0 to 2.7)
Serotype not included in Prevnar 13:380.7 (0.0 to 4.1)
Total Serotype not included in Prevnar 1356.3 (47.5 to 64.8)
Serotype clumps1.5 (0.2 to 5.2)
Serotype Missing/non-viable1.5 (0.2 to 5.2)
PrimaryPercentage of Streptococcus Pneumoniae Serotype Isolates From Middle Ear Fluid (MEF) Sample at Surveillance Year 2

The distribution of S pneumoniae serotypes isolated from MEF samples from children in the target population for vaccination over the surveillance year 2 were presented. The percentage of isolates of S pneumoniae serotypes included in Prevnar 13 (3, 7F, 19A, 19F) and not included in Prevnar 13 (6C, 7C, 9N, 10, 11, 12, 12F, 13, 15A, 15B, 15C, 15F, 16, 17, 20, 21, 22F, 23A, 23B, 31, 33A, 33F, 34, 35B, 35F, 38) along with total (both included and not included), clumps and missing or non-viable were computed along with exact 2-sided 95% CI based on the observed proportion of isolates. Missing or non-viable included isolates that were either not sent from an external laboratory, were non-viable or lost on culture prior to sending, or were non-viable on receipt in the central laboratory.'Number of isolates analyzed' signifies total number of isolates that were evaluable for this OM.

Time frame:
Surveillance Year 2
Reported as:
Number · percentage of isolates
Percentage of Streptococcus Pneumoniae Serotype Isolates From Middle Ear Fluid (MEF) Sample at Surveillance Year 2
percentage of isolatesMEF Population
Serotype included in Prevnar 13:36.3 (2.6 to 12.6)
Serotype included in Prevnar 13:7F0.0 (0.0 to 3.3)
Serotype included in Prevnar 13:19A23.4 (15.9 to 32.4)
Serotype included in Prevnar 13:19F1.8 (0.2 to 6.4)
Total Serotype included in Prevnar 1331.5 (23.0 to 41.0)
Serotype not included in Prevnar 13:6C4.5 (1.5 to 10.2)
Serotype not included in Prevnar 13:7C0.9 (0.0 to 4.9)
Serotype not included in Prevnar 13:9N0.0 (0.0 to 3.3)
Serotype not included in Prevnar 13:100.9 (0.0 to 4.9)
Serotype not included in Prevnar 13:117.2 (3.2 to 13.7)
Serotype not included in Prevnar 13:120.0 (0.0 to 3.3)
Serotype not included in Prevnar 13:12F0.9 (0.0 to 4.9)
Serotype not included in Prevnar 13:130.0 (0.0 to 3.3)
Serotype not included in Prevnar 13:15A0.9 (0.0 to 4.9)
Serotype not included in Prevnar 13:15B4.5 (1.5 to 10.2)
Serotype not included in Prevnar 13:15C2.7 (0.6 to 7.7)
Serotype not included in Prevnar 13:15F0.0 (0.0 to 3.3)
Serotype not included in Prevnar 13:162.7 (0.6 to 7.7)
Serotype not included in Prevnar 13:171.8 (0.2 to 6.4)
Serotype not included in Prevnar 13:200.0 (0.0 to 3.3)
Serotype not included in Prevnar 13:219.0 (4.4 to 15.9)
Serotype not included in Prevnar 13:22F0.9 (0.0 to 4.9)
Serotype not included in Prevnar 13:23A4.5 (1.5 to 10.2)
Serotype not included in Prevnar 13:23B7.2 (3.2 to 13.7)
Serotype not included in Prevnar 13:311.8 (0.2 to 6.4)
Serotype not included in Prevnar 13:33A0.0 (0.0 to 3.3)
Serotype not included in Prevnar 13:33F0.0 (0.0 to 3.3)
Serotype not included in Prevnar 13:340.9 (0.0 to 4.9)
Serotype not included in Prevnar 13:35B13.5 (7.8 to 21.3)
Serotype not included in Prevnar 13:35F0.9 (0.0 to 4.9)
Serotype not included in Prevnar 13:380.9 (0.0 to 4.9)
Total Serotype not included in Prevnar 1366.7 (57.1 to 75.3)
Serotype clumps0.9 (0.0 to 4.9)
Serotype Missing/non-viable0.9 (0.0 to 4.9)
PrimaryPercentage of Streptococcus Pneumoniae Serotype Isolates From Middle Ear Fluid (MEF) Sample at Surveillance Year 3

The distribution of S pneumoniae serotypes isolated from MEF samples from children in the target population for vaccination over the surveillance year 3 were presented. The percentage of isolates of S pneumoniae serotypes included in Prevnar 13 (3, 7F, 19A, 19F) and not included in Prevnar 13 (6C, 7C, 9N, 10, 11, 12, 12F, 13, 15A, 15B, 15C, 15F, 16, 17, 20, 21, 22F, 23A, 23B, 31, 33A, 33F, 34, 35B, 35F, 38) along with total (both included and not included), clumps and missing or non-viable were computed along with exact 2-sided 95% CI based on the observed proportion of isolates. Missing or non-viable included isolates that were either not sent from an external laboratory, were non-viable or lost on culture prior to sending, or were non-viable on receipt in the central laboratory.'Number of isolates analyzed' signifies total number of isolates that were evaluable for this OM.

Time frame:
Surveillance Year 3
Reported as:
Number · percentage of isolates
Percentage of Streptococcus Pneumoniae Serotype Isolates From Middle Ear Fluid (MEF) Sample at Surveillance Year 3
percentage of isolatesMEF Population
Serotype included in Prevnar 13:37.2 (3.2 to 13.7)
Serotype included in Prevnar 13:7F0.0 (0.0 to 3.3)
Serotype included in Prevnar 13:19A9.9 (5.1 to 17.0)
Serotype included in Prevnar 13:19F6.3 (2.6 to 12.6)
Total Serotype included in Prevnar 1323.4 (15.9 to 32.4)
Serotype not included in Prevnar 13:6C1.8 (0.2 to 6.4)
Serotype not included in Prevnar 13:7C0.0 (0.0 to 3.3)
Serotype not included in Prevnar 13:9N0.9 (0.0 to 4.9)
Serotype not included in Prevnar 13:102.7 (0.6 to 7.7)
Serotype not included in Prevnar 13:113.6 (1.0 to 9.0)
Serotype not included in Prevnar 13:120.0 (0.0 to 3.3)
Serotype not included in Prevnar 13:12F0.0 (0.0 to 3.3)
Serotype not included in Prevnar 13:130.0 (0.0 to 3.3)
Serotype not included in Prevnar 13:15A6.3 (2.6 to 12.6)
Serotype not included in Prevnar 13:15B5.4 (2.0 to 11.4)
Serotype not included in Prevnar 13:15C5.4 (2.0 to 11.4)
Serotype not included in Prevnar 13:15F0.9 (0.0 to 4.9)
Serotype not included in Prevnar 13:165.4 (2.0 to 11.4)
Serotype not included in Prevnar 13:170.9 (0.0 to 4.9)
Serotype not included in Prevnar 13:200.9 (0.0 to 4.9)
Serotype not included in Prevnar 13:215.4 (2.0 to 11.4)
Serotype not included in Prevnar 13:22F2.7 (0.6 to 7.7)
Serotype not included in Prevnar 13:23A2.7 (0.6 to 7.7)
Serotype not included in Prevnar 13:23B8.1 (3.8 to 14.8)
Serotype not included in Prevnar 13:314.5 (1.5 to 10.2)
Serotype not included in Prevnar 13:33A0.0 (0.0 to 3.3)
Serotype not included in Prevnar 13:33F1.8 (0.2 to 6.4)
Serotype not included in Prevnar 13:340.9 (0.0 to 4.9)
Serotype not included in Prevnar 13:35B10.8 (5.7 to 18.1)
Serotype not included in Prevnar 13:35F1.8 (0.2 to 6.4)
Serotype not included in Prevnar 13:381.8 (0.2 to 6.4)
Total Serotype not included in Prevnar 1374.8 (65.6 to 82.5)
Serotype clumps0.0 (0.0 to 3.3)
Serotype Missing/non-viable1.8 (0.2 to 6.4)
PrimaryPercentage of Streptococcus Pneumoniae Serotype Isolates From Mastoiditis Sample at Surveillance Year 1

The distribution of S pneumoniae serotypes isolated from mastoiditis samples from children in the target population for vaccination over the surveillance year 1 were presented. The percentage of isolates of S pneumoniae serotypes included in Prevnar 13 (1, 3, 7F, 14, 19A, 19F) and not included in Prevnar 13 (6C, 12, 15A, 15B, 15F, 21, 22F, 23A, 33F, 35B, 38) along with total (both included and not included in Prevnar 13 ), clumps and missing or non-viable were computed along with exact 2-sided 95% CI based on the observed proportion of isolates. Missing or non-viable included isolates that were either not sent from an external laboratory, were non-viable or lost on culture prior to sending, or were non-viable on receipt in the central laboratory.'Number of isolates analyzed' signifies total number of isolates that were evaluable for this OM.

Time frame:
Surveillance Year 1
Reported as:
Number · percentage of isolates
Percentage of Streptococcus Pneumoniae Serotype Isolates From Mastoiditis Sample at Surveillance Year 1
percentage of isolatesMastoid Population
Serotype included in Prevnar 13:10.0 (0.0 to 18.5)
Serotype included in Prevnar 13:30.0 (0.0 to 18.5)
Serotype included in Prevnar 13:7F0.0 (0.0 to 18.5)
Serotype included in Prevnar 13:140.0 (0.0 to 18.5)
Serotype included in Prevnar 13:19A38.9 (17.3 to 64.3)
Serotype included in Prevnar 13:19F11.1 (1.4 to 34.7)
Total Serotype included in Prevnar 1350.0 (26.0 to 74.0)
Serotype not included in Prevnar 13:6C5.6 (0.1 to 27.3)
Serotype not included in Prevnar 13:125.6 (0.1 to 27.3)
Serotype not included in Prevnar 13:15A5.6 (0.1 to 27.3)
Serotype not included in Prevnar 13:15B5.6 (0.1 to 27.3)
Serotype not included in Prevnar 13:15F0.0 (0.0 to 18.5)
Serotype not included in Prevnar 13:210.0 (0.0 to 18.5)
Serotype not included in Prevnar 13:22F11.1 (1.4 to 34.7)
Serotype not included in Prevnar 13:23A5.6 (0.1 to 27.3)
Serotype not included in Prevnar 13:33F0.0 (0.0 to 18.5)
Serotype not included in Prevnar 13:35B5.6 (0.1 to 27.3)
Serotype not included in Prevnar 13:385.6 (0.1 to 27.3)
Total Serotype not included in Prevnar 1350.0 (26.0 to 74.0)
Serotype missing/non-viable0.0 (0.0 to 18.5)
PrimaryPercentage of Streptococcus Pneumoniae Serotype Isolates From Mastoiditis Sample at Surveillance Year 2

The distribution of S pneumoniae serotypes isolated from mastoiditis samples from children in the target population for vaccination over the surveillance year 2 were presented. The percentage of isolates of S pneumoniae serotypes included in Prevnar 13 (1, 3, 7F, 14, 19A, 19F) and not included in Prevnar 13 (6C, 12, 15A, 15B, 15F, 21, 22F, 23A, 33F, 35B, 38) along with total (both included and not included in Prevnar 13 ), clumps and missing or non-viable were computed along with exact 2-sided 95% CI based on the observed proportion of isolates. Missing or non-viable included isolates that were either not sent from an external laboratory, were non-viable or lost on culture prior to sending, or were non-viable on receipt in the central laboratory.'Number of isolates analyzed' signifies total number of isolates that were evaluable for this OM.

Time frame:
Surveillance Year 2
Reported as:
Number · percentage of isolates
Percentage of Streptococcus Pneumoniae Serotype Isolates From Mastoiditis Sample at Surveillance Year 2
percentage of isolatesMastoid Population
Serotype included in Prevnar 13:10.0 (0.0 to 41.0)
Serotype included in Prevnar 13:328.6 (3.7 to 71.0)
Serotype included in Prevnar 13:7F0.0 (0.0 to 41.0)
Serotype included in Prevnar 13:140.0 (0.0 to 41.0)
Serotype included in Prevnar 13:19A71.4 (29.0 to 96.3)
Serotype included in Prevnar 13:19F0.0 (0.0 to 41.0)
Total Serotype included in Prevnar 13100.0 (59.0 to 100.0)
Serotype not included in Prevnar 13:6C0.0 (0.0 to 41.0)
Serotype not included in Prevnar 13:120.0 (0.0 to 41.0)
Serotype not included in Prevnar 13:15A0.0 (0.0 to 41.0)
Serotype not included in Prevnar 13:15B0.0 (0.0 to 41.0)
Serotype not included in Prevnar 13:15F0.0 (0.0 to 41.0)
Serotype not included in Prevnar 13:210.0 (0.0 to 41.0)
Serotype not included in Prevnar 13:22F0.0 (0.0 to 41.0)
Serotype not included in Prevnar 13:23A0.0 (0.0 to 41.0)
Serotype not included in Prevnar 13:33F0.0 (0.0 to 41.0)
Serotype not included in Prevnar 13:35B0.0 (0.0 to 41.0)
Serotype not included in Prevnar 13:380.0 (0.0 to 41.0)
Total Serotype not included in Prevnar 130.0 (0.0 to 41.0)
Serotype missing/non-viable0.0 (0.0 to 41.0)
PrimaryPercentage of Streptococcus Pneumoniae Serotype Isolates From Mastoiditis Sample at Surveillance Year 3

The distribution of S pneumoniae serotypes isolated from mastoiditis samples from children in the target population for vaccination over the surveillance year 3 were presented. The percentage of isolates of S pneumoniae serotypes included in Prevnar 13 (1, 3, 7F, 14, 19A, 19F) and not included in Prevnar 13 (6C, 12, 15A, 15B, 15F, 21, 22F, 23A, 33F, 35B, 38) along with total (both included and not included in Prevnar 13 ), clumps and missing or non-viable were computed along with exact 2-sided 95% CI based on the observed proportion of isolates. Missing or non-viable included isolates that were either not sent from an external laboratory, were non-viable or lost on culture prior to sending, or were non-viable on receipt in the central laboratory.'Number of isolates analyzed' signifies total number of isolates that were evaluable for this OM.

Time frame:
Surveillance Year 3
Reported as:
Number · percentage of isolates
Percentage of Streptococcus Pneumoniae Serotype Isolates From Mastoiditis Sample at Surveillance Year 3
percentage of isolatesMastoid Population
Serotype included in Prevnar 13:10.0 (0.0 to 33.6)
Serotype included in Prevnar 13:344.4 (13.7 to 78.8)
Serotype included in Prevnar 13:7F0.0 (0.0 to 33.6)
Serotype included in Prevnar 13:140.0 (0.0 to 33.6)
Serotype included in Prevnar 13:19A11.1 (0.3 to 48.2)
Serotype included in Prevnar 13:19F11.1 (0.3 to 48.2)
Total Serotype included in Prevnar 1366.7 (29.9 to 92.5)
Serotype not included in Prevnar 13:6C0.0 (0.0 to 33.6)
Serotype not included in Prevnar 13:120.0 (0.0 to 33.6)
Serotype not included in Prevnar 13:15A0.0 (0.0 to 33.6)
Serotype not included in Prevnar 13:15B0.0 (0.0 to 33.6)
Serotype not included in Prevnar 13:15F0.0 (0.0 to 33.6)
Serotype not included in Prevnar 13:210.0 (0.0 to 33.6)
Serotype not included in Prevnar 13:22F11.1 (0.3 to 48.2)
Serotype not included in Prevnar 13:23A0.0 (0.0 to 33.6)
Serotype not included in Prevnar 13:33F22.2 (2.8 to 60.0)
Serotype not included in Prevnar 13:35B0.0 (0.0 to 33.6)
Serotype not included in Prevnar 13:380.0 (0.0 to 33.6)
Total Serotype not included in Prevnar 1333.3 (7.5 to 70.1)
Serotype missing/non-viable0.0 (0.0 to 33.6)
SecondaryAntimicrobial Susceptibility of Streptococcus Pneumoniae Isolates for Amoxicillin: Middle Ear Fluid (MEF) Population

Antimicrobial susceptibility of S pneumoniae isolates for amoxicillin from MEF samples was categorized as resistant, susceptible or intermediate based on minimum inhibitory concentration (MIC) for each serotype at each year of the whole surveillance period. The percentage of S pneumoniae serotypes included 3, 6C, 7C, 9N, 10, 11, 12, 12F, 13, 15A, 15B, 15C, 15F, 16, 17, 19 A, 19 F, 20, 21, 22F, 23A, 23B, 31, 33A, 33F, 34, 35B, 35F, 38, clumps and missing or non-viable, which were to be computed along with exact 2-sided 95% CI based on the observed proportion of isolates. Missing or non-viable included isolates that were either not sent from an external laboratory, were non-viable or lost on culture prior to sending, or were non-viable on receipt in the central laboratory.'Number of isolates analyzed' signifies total number of isolates that were evaluable for this OM.

Time frame:
Surveillance Year 1, 2, 3
Reported as:
Number · percentage of isolates
Antimicrobial Susceptibility of Streptococcus Pneumoniae Isolates for Amoxicillin: Middle Ear Fluid (MEF) Population
percentage of isolatesMEF Population
Serotype 3 at Year 1:S3.0
Serotype 6C at Year 1:S3.0
Serotype 7C at Year 1:S0.0
Serotype 9N at Year 1:S0.7
Serotype 10 at Year 1:S1.5
Serotype 11 at Year 1:S1.5
Serotype 12 at Year 1:S0.0
Serotype 12F at Year 1:S0.0
Serotype 13 at Year 1:S0.0
Serotype 15A at Year 1:S1.5
Serotype 15B at Year 1:S0.7
Serotype 15C at Year 1:S3.0
Serotype 15F at Year 1:S0.0
Serotype 16 at Year 1:S0.0
Serotype 17 at Year 1:S0.0
Serotype 19A at Year 1:S3.0
Serotype 19F at Year 1:S0.7
Serotype 20 at Year 1:S0.0
Serotype 21 at Year 1:S1.5
Serotype 22F at Year 1:S0.0
Serotype 23A at Year 1:S1.5
Serotype 23B at Year 1:S0.7
Serotype 31 at Year 1:S0.0
Serotype 33A at Year 1:S0.7
Serotype 33F at Year 1:S0.0
Serotype 34 at Year 1:S0.0
Serotype 35B at Year 1:S3.0
Serotype 35F at Year 1:S0.0
Serotype 38 at Year 1:S0.0
Serotype clumps at Year 1:S0.0
Serotype Missing/non-viable at Year 1:S0.0
Serotype 3 at Year 2:S1.8
Serotype 6C at Year 2:S0.9
Serotype 7C at Year 2:S0.0
Serotype 9N at Year 2:S0.0
Serotype 10 at Year 2:S0.9
Serotype 11 at Year 2:S2.7
Serotype 12 at Year 2:S0.0
Serotype 12F at Year 2:S0.9
Serotype 13 at Year 2:S0.0
Serotype 15A at Year 2:S0.9
Serotype 15B at Year 2:S0.0
Serotype 15C at Year 2:S2.7
Serotype 15F at Year 2:S0.0
Serotype 16 at Year 2:S0.9
Serotype 17 at Year 2:S1.8
Serotype 19A at Year 2:S1.8
Serotype 19F at Year 2:S0.9
Serotype 20 at Year 2:S0.0
Serotype 21 at Year 2:S2.7
Serotype 22F at Year 2:S0.0
Serotype 23A at Year 2:S2.7
Serotype 23B at Year 2:S2.7
Serotype 31 at Year 2:S1.8
Serotype 33A at Year 2:S0.0
Serotype 33F at Year 2:S0.0
Serotype 34 at Year 2:S0.9
Serotype 35B at Year 2:S4.5
Serotype 35F at Year 2:S0.9
Serotype 38 at Year 2:S0.9
Serotype clumps at Year 2:S0.0
Serotype Missing/non-viable at Year 2:S0.9
Serotype 3 at Year 3:S3.6
Serotype 6C at Year 3:S0.0
Serotype 7C at Year 3:S0.0
Serotype 9N at Year 3:S0.9
Serotype 10 at Year 3:S1.8
Serotype 11 at Year 3:S1.8
Serotype 12 at Year 3:S0.0
Serotype 12F at Year 3:S0.0
Serotype 13 at Year 3:S0.0
Serotype 15A at Year 3:S2.7
Serotype 15B at Year 3:S3.6
Serotype 15C at Year 3:S0.9
Serotype 15F at Year 3:S0.0
Serotype 16 at Year 3:S3.6
Serotype 17 at Year 3:S0.9
Serotype 19A at Year 3:S0.0
Serotype 19F at Year 3:S1.8
Serotype 20 at Year 3:S0.9
Serotype 21 at Year 3:S1.8
Serotype 22F at Year 3:S0.0
Serotype 23A at Year 3:S2.7
Serotype 23B at Year 3:S6.3
Serotype 31 at Year 3:S1.8
Serotype 33A at Year 3:S0.0
Serotype 33F at Year 3:S0.0
Serotype 34 at Year 3:S0.0
Serotype 35B at Year 3:S5.4
Serotype 35F at Year 3:S0.0
Serotype 38 at Year 3:S0.9
Serotype clumps at Year 3:S0.0
Serotype Missing/non-viable at Year 3:S0.0
Serotype 3 at Year 1:I0.0
Serotype 6C at Year 1:I0.0
Serotype 7C at Year 1:I0.0
Serotype 9N at Year 1:I0.0
Serotype 10 at Year 1:I0.0
Serotype 11 at Year 1:I0.0
Serotype 12 at Year 1:I0.0
Serotype 12F at Year 1:I0.0
Serotype 13 at Year 1:I0.0
Serotype 15A at Year 1:I0.0
Serotype 15B at Year 1:I0.0
Serotype 15C at Year 1:I0.0
Serotype 15F at Year 1:I0.0
Serotype 16 at Year 1:I0.0
Serotype 17 at Year 1:I0.0
Serotype 19A at Year 1:I5.9
Serotype 19F at Year 1:I0.0
Serotype 20 at Year 1:I0.0
Serotype 21 at Year 1:I0.0
Serotype 22F at Year 1:I0.0
Serotype 23A at Year 1:I0.0
Serotype 23B at Year 1:I0.0
Serotype 31 at Year 1:I0.0
Serotype 33A at Year 1:I0.0
Serotype 33F at Year 1:I0.0
Serotype 34 at Year 1:I0.0
Serotype 35B at Year 1:I0.0
Serotype 35F at Year 1:I0.0
Serotype 38 at Year 1:I0.0
Serotype clumps at Year 1:I0.0
Serotype Missing/non-viable at Year 1:I0.0
Serotype 3 at Year 2:I0.0
Serotype 6C at Year 2:I0.0
Serotype 7C at Year 2:I0.0
Serotype 9N at Year 2:I0.0
Serotype 10 at Year 2:I0.0
Serotype 11 at Year 2:I0.0
Serotype 12 at Year 2:I0.0
Serotype 12F at Year 2:I0.0
Serotype 13 at Year 2:I0.0
Serotype 15A at Year 2:I0.0
Serotype 15B at Year 2:I0.0
Serotype 15C at Year 2:I0.0
Serotype 15F at Year 2:I0.0
Serotype 16 at Year 2:I0.0
Serotype 17 at Year 2:I0.0
Serotype 19A at Year 2:I0.0
Serotype 19F at Year 2:I0.0
Serotype 20 at Year 2:I0.0
Serotype 21 at Year 2:I0.0
Serotype 22F at Year 2:I0.0
Serotype 23A at Year 2:I0.0
Serotype 23B at Year 2:I0.0
Serotype 31 at Year 2:I0.0
Serotype 33A at Year 2:I0.0
Serotype 33F at Year 2:I0.0
Serotype 34 at Year 2:I0.0
Serotype 35B at Year 2:I0.0
Serotype 35F at Year 2:I0.0
Serotype 38 at Year 2:I0.0
Serotype clumps at Year 2:I0.0
Serotype Missing/non-viable at Year 2:I0.0
Serotype 3 at Year 3:I0.0
Serotype 6C at Year 3:I0.0
Serotype 7C at Year 3:I0.0
Serotype 9N at Year 3:I0.0
Serotype 10 at Year 3:I0.0
Serotype 11 at Year 3:I0.0
Serotype 12 at Year 3:I0.0
Serotype 12F at Year 3:I0.0
Serotype 13 at Year 3:I0.0
Serotype 15A at Year 3:I0.0
Serotype 15B at Year 3:I0.0
Serotype 15C at Year 3:I0.0
Serotype 15F at Year 3:I0.0
Serotype 16 at Year 3:I0.0
Serotype 17 at Year 3:I0.0
Serotype 19A at Year 3:I2.7
Serotype 19F at Year 3:I0.0
Serotype 20 at Year 3:I0.0
Serotype 21 at Year 3:I0.0
Serotype 22F at Year 3:I0.0
Serotype 23A at Year 3:I0.0
Serotype 23B at Year 3:I0.0
Serotype 31 at Year 3:I0.0
Serotype 33A at Year 3:I0.0
Serotype 33F at Year 3:I0.0
Serotype 34 at Year 3:I0.0
Serotype 35B at Year 3:I0.9
Serotype 35F at Year 3:I0.0
Serotype 38 at Year 3:I0.0
Serotype clumps at Year 3:I0.0
Serotype Missing/non-viable at Year 3:I0.0
Serotype 3 at Year 1:R0.0
Serotype 6C at Year 1:R0.0
Serotype 7C at Year 1:R0.0
Serotype 9N at Year 1:R0.0
Serotype 10 at Year 1:R0.0
Serotype 11 at Year 1:R0.0
Serotype 12 at Year 1:R0.0
Serotype 12F at Year 1:R0.0
Serotype 13 at Year 1:R0.0
Serotype 15A at Year 1:R0.0
Serotype 15B at Year 1:R0.0
Serotype 15C at Year 1:R0.0
Serotype 15F at Year 1:R0.0
Serotype 16 at Year 1:R0.0
Serotype 17 at Year 1:R0.0
Serotype 19A at Year 1:R0.0
Serotype 19F at Year 1:R0.0
Serotype 20 at Year 1:R0.0
Serotype 21 at Year 1:R0.0
Serotype 22F at Year 1:R0.0
Serotype 23A at Year 1:R0.0
Serotype 23B at Year 1:R0.0
Serotype 31 at Year 1:R0.0
Serotype 33A at Year 1:R0.0
Serotype 33F at Year 1:R0.0
Serotype 34 at Year 1:R0.0
Serotype 35B at Year 1:R0.0
Serotype 35F at Year 1:R0.0
Serotype 38 at Year 1:R0.0
Serotype clumps at Year 1:R0.0
Serotype Missing/non-viable at Year 1:R0.0
Serotype 3 at Year 2:R0.0
Serotype 6C at Year 2:R0.0
Serotype 7C at Year 2:R0.0
Serotype 9N at Year 2:R0.0
Serotype 10 at Year 2:R0.0
Serotype 11 at Year 2:R0.0
Serotype 12 at Year 2:R0.0
Serotype 12F at Year 2:R0.0
Serotype 13 at Year 2:R0.0
Serotype 15A at Year 2:R0.0
Serotype 15B at Year 2:R0.0
Serotype 15C at Year 2:R0.0
Serotype 15F at Year 2:R0.0
Serotype 16 at Year 2:R0.0
Serotype 17 at Year 2:R0.0
Serotype 19A at Year 2:R1.8
Serotype 19F at Year 2:R0.0
Serotype 20 at Year 2:R0.0
Serotype 21 at Year 2:R0.0
Serotype 22F at Year 2:R0.0
Serotype 23A at Year 2:R0.0
Serotype 23B at Year 2:R0.0
Serotype 31 at Year 2:R0.0
Serotype 33A at Year 2:R0.0
Serotype 33F at Year 2:R0.0
Serotype 34 at Year 2:R0.0
Serotype 35B at Year 2:R0.0
Serotype 35F at Year 2:R0.0
Serotype 38 at Year 2:R0.0
Serotype clumps at Year 2:R0.0
Serotype Missing/non-viable at Year 2:R0.0
Serotype 3 at Year 3:R0.0
Serotype 6C at Year 3:R0.0
Serotype 7C at Year 3:R0.0
Serotype 9N at Year 3:R0.0
Serotype 10 at Year 3:R0.0
Serotype 11 at Year 3:R0.0
Serotype 12 at Year 3:R0.0
Serotype 12F at Year 3:R0.0
Serotype 13 at Year 3:R0.0
Serotype 15A at Year 3:R0.0
Serotype 15B at Year 3:R0.0
Serotype 15C at Year 3:R0.0
Serotype 15F at Year 3:R0.0
Serotype 16 at Year 3:R0.0
Serotype 17 at Year 3:R0.0
Serotype 19A at Year 3:R2.7
Serotype 19F at Year 3:R0.0
Serotype 20 at Year 3:R0.0
Serotype 21 at Year 3:R0.0
Serotype 22F at Year 3:R0.0
Serotype 23A at Year 3:R0.0
Serotype 23B at Year 3:R0.0
Serotype 31 at Year 3:R0.0
Serotype 33A at Year 3:R0.0
Serotype 33F at Year 3:R0.0
Serotype 34 at Year 3:R0.0
Serotype 35B at Year 3:R0.0
Serotype 35F at Year 3:R0.0
Serotype 38 at Year 3:R0.0
Serotype clumps at Year 3:R0.0
Serotype Missing/non-viable at Year 3:R0.0
SecondaryAntimicrobial Susceptibility of Streptococcus Pneumoniae Isolates for Cefotaxime: Middle Ear Fluid (MEF) Population

Antimicrobial susceptibility of S pneumoniae isolates for cefotaxime from MEF samples was categorized as resistant, susceptible or intermediate based on MIC for each serotype at each year of the whole surveillance period. The percentage of S pneumoniae serotypes included 3, 6C, 7C, 9N, 10, 11, 12, 12F, 13, 15A, 15B, 15C, 15F, 16, 17, 19 A, 19 F, 20, 21, 22F, 23A, 23B, 31, 33A, 33F, 34, 35B, 35F, 38, clumps and missing or non-viable, which were to be computed along with exact 2-sided 95% CI based on the observed proportion of isolates. Missing or non-viable included isolates that were either not sent from an external laboratory, were non-viable or lost on culture prior to sending, or were non-viable on receipt in the central laboratory.'Number of isolates analyzed' signifies total number of isolates that were evaluable for this OM.

Time frame:
Surveillance Year 1, 2, 3
Reported as:
Number · percentage of isolates
Antimicrobial Susceptibility of Streptococcus Pneumoniae Isolates for Cefotaxime: Middle Ear Fluid (MEF) Population
percentage of isolatesMEF Population
Serotype 3 at Year 1:S1.5
Serotype 6C at Year 1:S2.2
Serotype 7C at Year 1:S0.7
Serotype 9N at Year 1:S0.0
Serotype 10 at Year 1:S0.7
Serotype 11 at Year 1:S0.0
Serotype 12 at Year 1:S0.7
Serotype 12F at Year 1:S0.0
Serotype 13 at Year 1:S0.0
Serotype 15A at Year 1:S2.2
Serotype 15B at Year 1:S2.2
Serotype 15C at Year 1:S0.7
Serotype 15F at Year 1:S0.0
Serotype 16 at Year 1:S0.7
Serotype 17 at Year 1:S0.0
Serotype 19A at Year 1:S5.9
Serotype 19F at Year 1:S0.0
Serotype 20 at Year 1:S0.0
Serotype 21 at Year 1:S0.7
Serotype 22F at Year 1:S0.7
Serotype 23A at Year 1:S0.7
Serotype 23B at Year 1:S0.7
Serotype 31 at Year 1:S2.2
Serotype 33A at Year 1:S0.0
Serotype 33F at Year 1:S2.2
Serotype 34 at Year 1:S0.0
Serotype 35B at Year 1:S3.0
Serotype 35F at Year 1:S0.0
Serotype 38 at Year 1:S0.0
Serotype clumps at Year 1:S1.5
Serotype Missing/non-viable at Year 1:S0.7
Serotype 3 at Year 2:S2.7
Serotype 6C at Year 2:S1.8
Serotype 7C at Year 2:S0.0
Serotype 9N at Year 2:S0.0
Serotype 10 at Year 2:S0.0
Serotype 11 at Year 2:S2.7
Serotype 12 at Year 2:S0.0
Serotype 12F at Year 2:S0.0
Serotype 13 at Year 2:S0.0
Serotype 15A at Year 2:S0.0
Serotype 15B at Year 2:S2.7
Serotype 15C at Year 2:S0.0
Serotype 15F at Year 2:S0.0
Serotype 16 at Year 2:S0.9
Serotype 17 at Year 2:S0.0
Serotype 19A at Year 2:S2.7
Serotype 19F at Year 2:S0.0
Serotype 20 at Year 2:S0.0
Serotype 21 at Year 2:S4.5
Serotype 22F at Year 2:S0.9
Serotype 23A at Year 2:S1.8
Serotype 23B at Year 2:S2.7
Serotype 31 at Year 2:S0.0
Serotype 33A at Year 2:S0.0
Serotype 33F at Year 2:S0.0
Serotype 34 at Year 2:S0.0
Serotype 35B at Year 2:S4.5
Serotype 35F at Year 2:S0.0
Serotype 38 at Year 2:S0.0
Serotype clumps at Year 2:S0.9
Serotype Missing/non-viable at Year 2:S0.0
Serotype 3 at Year 3:S0.9
Serotype 6C at Year 3:S0.9
Serotype 7C at Year 3:S0.0
Serotype 9N at Year 3:S0.0
Serotype 10 at Year 3:S0.0
Serotype 11 at Year 3:S0.9
Serotype 12 at Year 3:S0.0
Serotype 12F at Year 3:S0.0
Serotype 13 at Year 3:S0.0
Serotype 15A at Year 3:S1.8
Serotype 15B at Year 3:S0.0
Serotype 15C at Year 3:S2.7
Serotype 15F at Year 3:S0.0
Serotype 16 at Year 3:S0.0
Serotype 17 at Year 3:S0.0
Serotype 19A at Year 3:S1.8
Serotype 19F at Year 3:S2.7
Serotype 20 at Year 3:S0.0
Serotype 21 at Year 3:S0.9
Serotype 22F at Year 3:S0.0
Serotype 23A at Year 3:S0.0
Serotype 23B at Year 3:S0.9
Serotype 31 at Year 3:S0.9
Serotype 33A at Year 3:S0.0
Serotype 33F at Year 3:S1.8
Serotype 34 at Year 3:S0.0
Serotype 35B at Year 3:S2.7
Serotype 35F at Year 3:S0.9
Serotype 38 at Year 3:S0.0
Serotype clumps at Year 3:S0.0
Serotype Missing/non-viable at Year 3:S0.9
Serotype 3 at Year 1:I0.0
Serotype 6C at Year 1:I0.0
Serotype 7C at Year 1:I0.0
Serotype 9N at Year 1:I0.0
Serotype 10 at Year 1:I0.0
Serotype 11 at Year 1:I0.0
Serotype 12 at Year 1:I0.0
Serotype 12F at Year 1:I0.0
Serotype 13 at Year 1:I0.0
Serotype 15A at Year 1:I0.0
Serotype 15B at Year 1:I0.0
Serotype 15C at Year 1:I0.0
Serotype 15F at Year 1:I0.0
Serotype 16 at Year 1:I0.0
Serotype 17 at Year 1:I0.0
Serotype 19A at Year 1:I7.4
Serotype 19F at Year 1:I0.7
Serotype 20 at Year 1:I0.0
Serotype 21 at Year 1:I0.0
Serotype 22F at Year 1:I0.0
Serotype 23A at Year 1:I0.0
Serotype 23B at Year 1:I0.0
Serotype 31 at Year 1:I0.0
Serotype 33A at Year 1:I0.0
Serotype 33F at Year 1:I0.0
Serotype 34 at Year 1:I0.0
Serotype 35B at Year 1:I0.7
Serotype 35F at Year 1:I0.0
Serotype 38 at Year 1:I0.0
Serotype clumps at Year 1:I0.0
Serotype Missing/non-viable at Year 1:I0.0
Serotype 3 at Year 2:I0.0
Serotype 6C at Year 2:I0.0
Serotype 7C at Year 2:I0.0
Serotype 9N at Year 2:I0.0
Serotype 10 at Year 2:I0.0
Serotype 11 at Year 2:I0.9
Serotype 12 at Year 2:I0.0
Serotype 12F at Year 2:I0.0
Serotype 13 at Year 2:I0.0
Serotype 15A at Year 2:I0.0
Serotype 15B at Year 2:I0.0
Serotype 15C at Year 2:I0.0
Serotype 15F at Year 2:I0.0
Serotype 16 at Year 2:I0.0
Serotype 17 at Year 2:I0.0
Serotype 19A at Year 2:I4.5
Serotype 19F at Year 2:I0.0
Serotype 20 at Year 2:I0.0
Serotype 21 at Year 2:I0.0
Serotype 22F at Year 2:I0.0
Serotype 23A at Year 2:I0.0
Serotype 23B at Year 2:I0.9
Serotype 31 at Year 2:I0.0
Serotype 33A at Year 2:I0.0
Serotype 33F at Year 2:I0.0
Serotype 34 at Year 2:I0.0
Serotype 35B at Year 2:I0.9
Serotype 35F at Year 2:I0.0
Serotype 38 at Year 2:I0.0
Serotype clumps at Year 2:I0.0
Serotype Missing/non-viable at Year 2:I0.0
Serotype 3 at Year 3:I0.0
Serotype 6C at Year 3:I0.0
Serotype 7C at Year 3:I0.0
Serotype 9N at Year 3:I0.0
Serotype 10 at Year 3:I0.0
Serotype 11 at Year 3:I0.0
Serotype 12 at Year 3:I0.0
Serotype 12F at Year 3:I0.0
Serotype 13 at Year 3:I0.0
Serotype 15A at Year 3:I0.0
Serotype 15B at Year 3:I0.0
Serotype 15C at Year 3:I0.0
Serotype 15F at Year 3:I0.0
Serotype 16 at Year 3:I0.0
Serotype 17 at Year 3:I0.0
Serotype 19A at Year 3:I0.0
Serotype 19F at Year 3:I0.9
Serotype 20 at Year 3:I0.0
Serotype 21 at Year 3:I0.0
Serotype 22F at Year 3:I0.0
Serotype 23A at Year 3:I0.0
Serotype 23B at Year 3:I0.0
Serotype 31 at Year 3:I0.0
Serotype 33A at Year 3:I0.0
Serotype 33F at Year 3:I0.0
Serotype 34 at Year 3:I0.0
Serotype 35B at Year 3:I0.0
Serotype 35F at Year 3:I0.0
Serotype 38 at Year 3:I0.0
Serotype clumps at Year 3:I0.0
Serotype Missing/non-viable at Year 3:I0.0
Serotype 3 at Year 1:R0.0
Serotype 6C at Year 1:R0.0
Serotype 7C at Year 1:R0.0
Serotype 9N at Year 1:R0.0
Serotype 10 at Year 1:R0.0
Serotype 11 at Year 1:R0.0
Serotype 12 at Year 1:R0.0
Serotype 12F at Year 1:R0.0
Serotype 13 at Year 1:R0.0
Serotype 15A at Year 1:R0.0
Serotype 15B at Year 1:R0.0
Serotype 15C at Year 1:R0.0
Serotype 15F at Year 1:R0.0
Serotype 16 at Year 1:R0.0
Serotype 17 at Year 1:R0.0
Serotype 19A at Year 1:R1.5
Serotype 19F at Year 1:R0.0
Serotype 20 at Year 1:R0.0
Serotype 21 at Year 1:R0.0
Serotype 22F at Year 1:R0.0
Serotype 23A at Year 1:R0.0
Serotype 23B at Year 1:R0.0
Serotype 31 at Year 1:R0.0
Serotype 33A at Year 1:R0.0
Serotype 33F at Year 1:R0.0
Serotype 34 at Year 1:R0.0
Serotype 35B at Year 1:R0.0
Serotype 35F at Year 1:R0.0
Serotype 38 at Year 1:R0.0
Serotype clumps at Year 1:R0.0
Serotype Missing/non-viable at Year 1:R0.0
Serotype 3 at Year 2:R0.0
Serotype 6C at Year 2:R0.0
Serotype 7C at Year 2:R0.0
Serotype 9N at Year 2:R0.0
Serotype 10 at Year 2:R0.0
Serotype 11 at Year 2:R0.0
Serotype 12 at Year 2:R0.0
Serotype 12F at Year 2:R0.0
Serotype 13 at Year 2:R0.0
Serotype 15A at Year 2:R0.0
Serotype 15B at Year 2:R0.0
Serotype 15C at Year 2:R0.0
Serotype 15F at Year 2:R0.0
Serotype 16 at Year 2:R0.0
Serotype 17 at Year 2:R0.0
Serotype 19A at Year 2:R0.0
Serotype 19F at Year 2:R0.0
Serotype 20 at Year 2:R0.0
Serotype 21 at Year 2:R0.0
Serotype 22F at Year 2:R0.0
Serotype 23A at Year 2:R0.0
Serotype 23B at Year 2:R0.0
Serotype 31 at Year 2:R0.0
Serotype 33A at Year 2:R0.0
Serotype 33F at Year 2:R0.0
Serotype 34 at Year 2:R0.0
Serotype 35B at Year 2:R0.0
Serotype 35F at Year 2:R0.0
Serotype 38 at Year 2:R0.0
Serotype clumps at Year 2:R0.0
Serotype Missing/non-viable at Year 2:R0.0
Serotype 3 at Year 3:R0.0
Serotype 6C at Year 3:R0.0
Serotype 7C at Year 3:R0.0
Serotype 9N at Year 3:R0.0
Serotype 10 at Year 3:R0.0
Serotype 11 at Year 3:R0.0
Serotype 12 at Year 3:R0.0
Serotype 12F at Year 3:R0.0
Serotype 13 at Year 3:R0.0
Serotype 15A at Year 3:R0.0
Serotype 15B at Year 3:R0.0
Serotype 15C at Year 3:R0.0
Serotype 15F at Year 3:R0.0
Serotype 16 at Year 3:R0.0
Serotype 17 at Year 3:R0.0
Serotype 19A at Year 3:R0.0
Serotype 19F at Year 3:R0.0
Serotype 20 at Year 3:R0.0
Serotype 21 at Year 3:R0.0
Serotype 22F at Year 3:R0.0
Serotype 23A at Year 3:R0.0
Serotype 23B at Year 3:R0.0
Serotype 31 at Year 3:R0.0
Serotype 33A at Year 3:R0.0
Serotype 33F at Year 3:R0.0
Serotype 34 at Year 3:R0.0
Serotype 35B at Year 3:R0.0
Serotype 35F at Year 3:R0.0
Serotype 38 at Year 3:R0.0
Serotype clumps at Year 3:R0.0
Serotype Missing/non-viable at Year 3:R0.0
SecondaryAntimicrobial Susceptibility of Streptococcus Pneumoniae Isolates for Ceftriaxone: Middle Ear Fluid (MEF) Population

Antimicrobial susceptibility of S pneumoniae isolates for ceftriaxone from MEF samples was categorized as resistant, susceptible or intermediate based on MIC for each serotype at each year of the whole surveillance period. The percentage of S pneumoniae serotypes included 3, 6C, 7C, 9N, 10, 11, 12, 12F, 13, 15A, 15B, 15C, 15F, 16, 17, 19 A, 19 F, 20, 21, 22F, 23A, 23B, 31, 33A, 33F, 34, 35B, 35F, 38, clumps and missing or non-viable, which were to be computed along with exact 2-sided 95% CI based on the observed proportion of isolates. Missing or non-viable included isolates that were either not sent from an external laboratory, were non-viable or lost on culture prior to sending, or were non-viable on receipt in the central laboratory.'Number of isolates analyzed' signifies total number of isolates that were evaluable for this OM.

Time frame:
Surveillance Year 1, 2, 3
Reported as:
Number · percentage of isolates
Antimicrobial Susceptibility of Streptococcus Pneumoniae Isolates for Ceftriaxone: Middle Ear Fluid (MEF) Population
percentage of isolatesMEF Population
Serotype 3 at Year 1:S5.9
Serotype 6C at Year 1:S6.7
Serotype 7C at Year 1:S1.5
Serotype 9N at Year 1:S2.2
Serotype 10 at Year 1:S3.0
Serotype 11 at Year 1:S3.7
Serotype 12 at Year 1:S0.7
Serotype 12F at Year 1:S0.0
Serotype 13 at Year 1:S0.7
Serotype 15A at Year 1:S3.7
Serotype 15B at Year 1:S4.4
Serotype 15C at Year 1:S3.7
Serotype 15F at Year 1:S0.0
Serotype 16 at Year 1:S1.5
Serotype 17 at Year 1:S0.0
Serotype 19A at Year 1:S20.7
Serotype 19F at Year 1:S1.5
Serotype 20 at Year 1:S0.0
Serotype 21 at Year 1:S3.0
Serotype 22F at Year 1:S1.5
Serotype 23A at Year 1:S3.0
Serotype 23B at Year 1:S0.7
Serotype 31 at Year 1:S2.2
Serotype 33A at Year 1:S0.7
Serotype 33F at Year 1:S3.0
Serotype 34 at Year 1:S0.0
Serotype 35B at Year 1:S6.7
Serotype 35F at Year 1:S0.0
Serotype 38 at Year 1:S0.7
Serotype clumps at Year 1:S0.7
Serotype Missing/non-viable at Year 1:S0.7
Serotype 3 at Year 2:S6.3
Serotype 6C at Year 2:S3.6
Serotype 7C at Year 2:S0.0
Serotype 9N at Year 2:S0.0
Serotype 10 at Year 2:S0.9
Serotype 11 at Year 2:S6.3
Serotype 12 at Year 2:S0.0
Serotype 12F at Year 2:S0.9
Serotype 13 at Year 2:S0.0
Serotype 15A at Year 2:S0.9
Serotype 15B at Year 2:S3.6
Serotype 15C at Year 2:S2.7
Serotype 15F at Year 2:S0.0
Serotype 16 at Year 2:S2.7
Serotype 17 at Year 2:S1.8
Serotype 19A at Year 2:S13.5
Serotype 19F at Year 2:S0.9
Serotype 20 at Year 2:S0.0
Serotype 21 at Year 2:S9.0
Serotype 22F at Year 2:S0.9
Serotype 23A at Year 2:S4.5
Serotype 23B at Year 2:S6.3
Serotype 31 at Year 2:S1.8
Serotype 33A at Year 2:S0.0
Serotype 33F at Year 2:S0.0
Serotype 34 at Year 2:S0.9
Serotype 35B at Year 2:S11.7
Serotype 35F at Year 2:S0.9
Serotype 38 at Year 2:S0.9
Serotype clumps at Year 2:S0.9
Serotype Missing/non-viable at Year 2:S0.9
Serotype 3 at Year 3:S6.3
Serotype 6C at Year 3:S1.8
Serotype 7C at Year 3:S0.0
Serotype 9N at Year 3:S0.9
Serotype 10 at Year 3:S2.7
Serotype 11 at Year 3:S3.6
Serotype 12 at Year 3:S0.0
Serotype 12F at Year 3:S0.0
Serotype 13 at Year 3:S0.0
Serotype 15A at Year 3:S6.3
Serotype 15B at Year 3:S4.5
Serotype 15C at Year 3:S5.4
Serotype 15F at Year 3:S0.9
Serotype 16 at Year 3:S4.5
Serotype 17 at Year 3:S0.9
Serotype 19A at Year 3:S5.4
Serotype 19F at Year 3:S4.5
Serotype 20 at Year 3:S0.9
Serotype 21 at Year 3:S5.4
Serotype 22F at Year 3:S1.8
Serotype 23A at Year 3:S2.7
Serotype 23B at Year 3:S8.1
Serotype 31 at Year 3:S4.5
Serotype 33A at Year 3:S0.0
Serotype 33F at Year 3:S1.8
Serotype 34 at Year 3:S0.9
Serotype 35B at Year 3:S9.9
Serotype 35F at Year 3:S1.8
Serotype 38 at Year 3:S0.9
Serotype clumps at Year 3:S0.0
Serotype Missing/non-viable at Year 3:S0.9
Serotype 3 at Year 1:I0.0
Serotype 6C at Year 1:I0.0
Serotype 7C at Year 1:I0.0
Serotype 9N at Year 1:I0.0
Serotype 10 at Year 1:I0.0
Serotype 11 at Year 1:I0.0
Serotype 12 at Year 1:I0.0
Serotype 12F at Year 1:I0.0
Serotype 13 at Year 1:I0.0
Serotype 15A at Year 1:I0.0
Serotype 15B at Year 1:I0.0
Serotype 15C at Year 1:I0.0
Serotype 15F at Year 1:I0.0
Serotype 16 at Year 1:I0.0
Serotype 17 at Year 1:I0.0
Serotype 19A at Year 1:I8.1
Serotype 19F at Year 1:I0.7
Serotype 20 at Year 1:I0.0
Serotype 21 at Year 1:I0.0
Serotype 22F at Year 1:I0.0
Serotype 23A at Year 1:I0.0
Serotype 23B at Year 1:I0.0
Serotype 31 at Year 1:I0.0
Serotype 33A at Year 1:I0.0
Serotype 33F at Year 1:I0.0
Serotype 34 at Year 1:I0.0
Serotype 35B at Year 1:I0.0
Serotype 35F at Year 1:I0.0
Serotype 38 at Year 1:I0.0
Serotype clumps at Year 1:I0.0
Serotype Missing/non-viable at Year 1:I0.0
Serotype 3 at Year 2:I0.0
Serotype 6C at Year 2:I0.0
Serotype 7C at Year 2:I0.0
Serotype 9N at Year 2:I0.0
Serotype 10 at Year 2:I0.0
Serotype 11 at Year 2:I0.9
Serotype 12 at Year 2:I0.0
Serotype 12F at Year 2:I0.0
Serotype 13 at Year 2:I0.0
Serotype 15A at Year 2:I0.0
Serotype 15B at Year 2:I0.0
Serotype 15C at Year 2:I0.0
Serotype 15F at Year 2:I0.0
Serotype 16 at Year 2:I0.0
Serotype 17 at Year 2:I0.0
Serotype 19A at Year 2:I7.2
Serotype 19F at Year 2:I0.0
Serotype 20 at Year 2:I0.0
Serotype 21 at Year 2:I0.0
Serotype 22F at Year 2:I0.0
Serotype 23A at Year 2:I0.0
Serotype 23B at Year 2:I0.9
Serotype 31 at Year 2:I0.0
Serotype 33A at Year 2:I0.0
Serotype 33F at Year 2:I0.0
Serotype 34 at Year 2:I0.0
Serotype 35B at Year 2:I0.0
Serotype 35F at Year 2:I0.0
Serotype 38 at Year 2:I0.0
Serotype clumps at Year 2:I0.0
Serotype Missing/non-viable at Year 2:I0.0
Serotype 3 at Year 3:I0.9
Serotype 6C at Year 3:I0.0
Serotype 7C at Year 3:I0.0
Serotype 9N at Year 3:I0.0
Serotype 10 at Year 3:I0.0
Serotype 11 at Year 3:I0.0
Serotype 12 at Year 3:I0.0
Serotype 12F at Year 3:I0.0
Serotype 13 at Year 3:I0.0
Serotype 15A at Year 3:I0.0
Serotype 15B at Year 3:I0.0
Serotype 15C at Year 3:I0.0
Serotype 15F at Year 3:I0.0
Serotype 16 at Year 3:I0.0
Serotype 17 at Year 3:I0.0
Serotype 19A at Year 3:I2.7
Serotype 19F at Year 3:I0.9
Serotype 20 at Year 3:I0.0
Serotype 21 at Year 3:I0.0
Serotype 22F at Year 3:I0.0
Serotype 23A at Year 3:I0.0
Serotype 23B at Year 3:I0.0
Serotype 31 at Year 3:I0.0
Serotype 33A at Year 3:I0.0
Serotype 33F at Year 3:I0.0
Serotype 34 at Year 3:I0.0
Serotype 35B at Year 3:I0.0
Serotype 35F at Year 3:I0.0
Serotype 38 at Year 3:I0.0
Serotype clumps at Year 3:I0.0
Serotype Missing/non-viable at Year 3:I0.0
Serotype 3 at Year 1:R0.0
Serotype 6C at Year 1:R0.0
Serotype 7C at Year 1:R0.0
Serotype 9N at Year 1:R0.0
Serotype 10 at Year 1:R0.0
Serotype 11 at Year 1:R0.0
Serotype 12 at Year 1:R0.0
Serotype 12F at Year 1:R0.0
Serotype 13 at Year 1:R0.0
Serotype 15A at Year 1:R0.0
Serotype 15B at Year 1:R0.0
Serotype 15C at Year 1:R0.0
Serotype 15F at Year 1:R0.0
Serotype 16 at Year 1:R0.0
Serotype 17 at Year 1:R0.0
Serotype 19A at Year 1:R1.5
Serotype 19F at Year 1:R0.0
Serotype 20 at Year 1:R0.0
Serotype 21 at Year 1:R0.0
Serotype 22F at Year 1:R0.0
Serotype 23A at Year 1:R0.0
Serotype 23B at Year 1:R0.0
Serotype 31 at Year 1:R0.0
Serotype 33A at Year 1:R0.0
Serotype 33F at Year 1:R0.0
Serotype 34 at Year 1:R0.0
Serotype 35B at Year 1:R0.0
Serotype 35F at Year 1:R0.0
Serotype 38 at Year 1:R0.0
Serotype clumps at Year 1:R0.0
Serotype Missing/non-viable at Year 1:R0.0
Serotype 3 at Year 2:R0.0
Serotype 6C at Year 2:R0.0
Serotype 7C at Year 2:R0.0
Serotype 9N at Year 2:R0.0
Serotype 10 at Year 2:R0.0
Serotype 11 at Year 2:R0.0
Serotype 12 at Year 2:R0.0
Serotype 12F at Year 2:R0.0
Serotype 13 at Year 2:R0.0
Serotype 15A at Year 2:R0.0
Serotype 15B at Year 2:R0.0
Serotype 15C at Year 2:R0.0
Serotype 15F at Year 2:R0.0
Serotype 16 at Year 2:R0.0
Serotype 17 at Year 2:R0.0
Serotype 19A at Year 2:R0.0
Serotype 19F at Year 2:R0.0
Serotype 20 at Year 2:R0.0
Serotype 21 at Year 2:R0.0
Serotype 22F at Year 2:R0.0
Serotype 23A at Year 2:R0.0
Serotype 23B at Year 2:R0.0
Serotype 31 at Year 2:R0.0
Serotype 33A at Year 2:R0.0
Serotype 33F at Year 2:R0.0
Serotype 34 at Year 2:R0.0
Serotype 35B at Year 2:R0.0
Serotype 35F at Year 2:R0.0
Serotype 38 at Year 2:R0.0
Serotype clumps at Year 2:R0.0
Serotype Missing/non-viable at Year 2:R0.0
Serotype 3 at Year 3:R0.0
Serotype 6C at Year 3:R0.0
Serotype 7C at Year 3:R0.0
Serotype 9N at Year 3:R0.0
Serotype 10 at Year 3:R0.0
Serotype 11 at Year 3:R0.0
Serotype 12 at Year 3:R0.0
Serotype 12F at Year 3:R0.0
Serotype 13 at Year 3:R0.0
Serotype 15A at Year 3:R0.0
Serotype 15B at Year 3:R0.0
Serotype 15C at Year 3:R0.0
Serotype 15F at Year 3:R0.0
Serotype 16 at Year 3:R0.0
Serotype 17 at Year 3:R0.0
Serotype 19A at Year 3:R0.9
Serotype 19F at Year 3:R0.0
Serotype 20 at Year 3:R0.0
Serotype 21 at Year 3:R0.0
Serotype 22F at Year 3:R0.9
Serotype 23A at Year 3:R0.0
Serotype 23B at Year 3:R0.0
Serotype 31 at Year 3:R0.0
Serotype 33A at Year 3:R0.0
Serotype 33F at Year 3:R0.0
Serotype 34 at Year 3:R0.0
Serotype 35B at Year 3:R0.0
Serotype 35F at Year 3:R0.0
Serotype 38 at Year 3:R0.0
Serotype clumps at Year 3:R0.0
Serotype Missing/non-viable at Year 3:R0.0
SecondaryAntimicrobial Susceptibility of Streptococcus Pneumoniae Isolates for Clindamycin: Middle Ear Fluid (MEF) Population

Antimicrobial susceptibility of S pneumoniae isolates for clindamycin from MEF samples was categorized as resistant, susceptible or intermediate based on MIC for each serotype at each year of the whole surveillance period. The percentage of S pneumoniae serotypes included 3, 6C, 7C, 9N, 10, 11, 12, 12F, 13, 15A, 15B, 15C, 15F, 16, 17, 19 A, 19 F, 20, 21, 22F, 23A, 23B, 31, 33A, 33F, 34, 35B, 35F, 38, clumps and missing or non-viable, which were to be computed along with exact 2-sided 95% CI based on the observed proportion of isolates. Missing or non-viable included isolates that were either not sent from an external laboratory, were non-viable or lost on culture prior to sending, or were non-viable on receipt in the central laboratory.'Number of isolates analyzed' signifies total number of isolates that were evaluable for this OM.

Time frame:
Surveillance Year 1, 2, 3
Reported as:
Number · percentage of isolates
Antimicrobial Susceptibility of Streptococcus Pneumoniae Isolates for Clindamycin: Middle Ear Fluid (MEF) Population
percentage of isolatesMEF Population
Serotype 3 at Year 1:S4.4
Serotype 9N at Year 1:S0.0
Serotype 10 at Year 1:S1.5
Serotype 11 at Year 1:S1.5
Serotype 12 at Year 1:S0.7
Serotype 12F at Year 1:S0.0
Serotype 13 at Year 1:S0.0
Serotype 15A at Year 1:S0.7
Serotype 15B at Year 1:S2.2
Serotype 15C at Year 1:S3.0
Serotype 15F at Year 1:S0.0
Serotype 16 at Year 1:S0.0
Serotype 17 at Year 1:S0.0
Serotype 19A at Year 1:S3.0
Serotype 19F at Year 1:S0.7
Serotype 20 at Year 1:S0.0
Serotype 21 at Year 1:S1.5
Serotype 22F at Year 1:S0.0
Serotype 23A at Year 1:S2.2
Serotype 23B at Year 1:S0.7
Serotype 31 at Year 1:S1.5
Serotype 33A at Year 1:S0.7
Serotype 33F at Year 1:S0.7
Serotype 34 at Year 1:S0.0
Serotype 35B at Year 1:S5.9
Serotype 35F at Year 1:S0.0
Serotype 38 at Year 1:S0.0
Serotype clumps at Year 1:S0.0
Serotype Missing/non-viable at Year 1:S0.0
Serotype 3 at Year 2:S4.5
Serotype 6C at Year 2:S2.7
Serotype 7C at Year 2:S0.0
Serotype 9N at Year 2:S0.0
Serotype 10 at Year 2:S0.9
Serotype 11 at Year 2:S3.6
Serotype 12 at Year 2:S0.0
Serotype 12F at Year 2:S0.9
Serotype 13 at Year 2:S0.0
Serotype 15A at Year 2:S0.0
Serotype 15B at Year 2:S1.8
Serotype 15C at Year 2:S2.7
Serotype 15F at Year 2:S0.0
Serotype 16 at Year 2:S1.8
Serotype 17 at Year 2:S1.8
Serotype 19A at Year 2:S2.7
Serotype 19F at Year 2:S0.9
Serotype 20 at Year 2:S0.0
Serotype 21 at Year 2:S5.4
Serotype 22F at Year 2:S0.0
Serotype 23A at Year 2:S1.8
Serotype 23B at Year 2:S6.3
Serotype 31 at Year 2:S1.8
Serotype 33A at Year 2:S0.0
Serotype 33F at Year 2:S0.0
Serotype 34 at Year 2:S0.9
Serotype 35B at Year 2:S9.0
Serotype 35F at Year 2:S0.9
Serotype 38 at Year 2:S0.9
Serotype clumps at Year 2:S0.0
Serotype Missing/non-viable at Year 2:S0.9
Serotype 3 at Year 3:S3.6
Serotype 6C at Year 3:S0.0
Serotype 7C at Year 3:S0.0
Serotype 9N at Year 3:S0.9
Serotype 10 at Year 3:S1.8
Serotype 11 at Year 3:S1.8
Serotype 12 at Year 3:S0.0
Serotype 12F at Year 3:S0.0
Serotype 13 at Year 3:S0.0
Serotype 15A at Year 3:S2.7
Serotype 15B at Year 3:S2.7
Serotype 15C at Year 3:S2.7
Serotype 15F at Year 3:S0.0
Serotype 16 at Year 3:S3.6
Serotype 17 at Year 3:S0.9
Serotype 19A at Year 3:S1.8
Serotype 19F at Year 3:S2.7
Serotype 20 at Year 3:S0.9
Serotype 21 at Year 3:S1.8
Serotype 22F at Year 3:S0.0
Serotype 23A at Year 3:S2.7
Serotype 23B at Year 3:S7.2
Serotype 31 at Year 3:S2.7
Serotype 33A at Year 3:S0.0
Serotype 33F at Year 3:S1.8
Serotype 34 at Year 3:S0.0
Serotype 35B at Year 3:S6.3
Serotype 35F at Year 3:S0.9
Serotype 38 at Year 3:S0.9
Serotype clumps at Year 3:S0.0
Serotype Missing/non-viable at Year 3:S1.8
Serotype 6C at Year 1:S4.4
Serotype 7C at Year 1:S0.0
Serotype 3 at Year 1:I0.0
Serotype 6C at Year 1:I0.0
Serotype 7C at Year 1:I0.0
Serotype 9N at Year 1:I0.7
Serotype 10 at Year 1:I0.0
Serotype 11 at Year 1:I0.0
Serotype 12 at Year 1:I0.0
Serotype 12F at Year 1:I0.0
Serotype 13 at Year 1:I0.0
Serotype 15A at Year 1:I0.0
Serotype 15B at Year 1:I0.0
Serotype 15C at Year 1:I0.0
Serotype 15F at Year 1:I0.0
Serotype 16 at Year 1:I0.0
Serotype 17 at Year 1:I0.0
Serotype 19A at Year 1:I5.2
Serotype 19F at Year 1:I0.0
Serotype 20 at Year 1:I0.0
Serotype 21 at Year 1:I0.0
Serotype 22F at Year 1:I0.0
Serotype 23A at Year 1:I0.0
Serotype 23B at Year 1:I0.0
Serotype 31 at Year 1:I0.0
Serotype 33A at Year 1:I0.0
Serotype 33F at Year 1:I0.7
Serotype 34 at Year 1:I0.0
Serotype 35B at Year 1:I0.0
Serotype 35F at Year 1:I0.0
Serotype 38 at Year 1:I0.0
Serotype clumps at Year 1:I0.0
Serotype Missing/non-viable at Year 1:I0.0
Serotype 3 at Year 2:I0.0
Serotype 6C at Year 2:I0.0
Serotype 7C at Year 2:I0.0
Serotype 9N at Year 2:I0.0
Serotype 10 at Year 2:I0.0
Serotype 11 at Year 2:I0.0
Serotype 12 at Year 2:I0.0
Serotype 12F at Year 2:I0.0
Serotype 13 at Year 2:I0.0
Serotype 15A at Year 2:I0.0
Serotype 15B at Year 2:I0.0
Serotype 15C at Year 2:I0.0
Serotype 15F at Year 2:I0.0
Serotype 16 at Year 2:I0.0
Serotype 17 at Year 2:I0.0
Serotype 19A at Year 2:I0.9
Serotype 19F at Year 2:I0.0
Serotype 20 at Year 2:I0.0
Serotype 21 at Year 2:I0.0
Serotype 22F at Year 2:I0.0
Serotype 23A at Year 2:I0.9
Serotype 23B at Year 2:I0.0
Serotype 31 at Year 2:I0.0
Serotype 33A at Year 2:I0.0
Serotype 33F at Year 2:I0.0
Serotype 34 at Year 2:I0.0
Serotype 35B at Year 2:I10.9
Serotype 35F at Year 2:I0.0
Serotype 38 at Year 2:I0.0
Serotype clumps at Year 2:I0.0
Serotype Missing/non-viable at Year 2:I0.0
Serotype 3 at Year 3:I0.0
Serotype 6C at Year 3:I0.0
Serotype 7C at Year 3:I0.0
Serotype 9N at Year 3:I0.0
Serotype 10 at Year 3:I0.0
Serotype 11 at Year 3:I0.0
Serotype 12 at Year 3:I0.0
Serotype 12F at Year 3:I0.0
Serotype 13 at Year 3:I0.0
Serotype 15A at Year 3:I0.0
Serotype 15B at Year 3:I0.9
Serotype 15C at Year 3:I0.0
Serotype 15F at Year 3:I0.0
Serotype 16 at Year 3:I0.0
Serotype 17 at Year 3:I0.0
Serotype 19A at Year 3:I0.0
Serotype 19F at Year 3:I0.9
Serotype 20 at Year 3:I0.0
Serotype 21 at Year 3:I0.0
Serotype 22F at Year 3:I0.0
Serotype 23A at Year 3:I0.0
Serotype 23B at Year 3:I0.0
Serotype 31 at Year 3:I0.0
Serotype 33A at Year 3:I0.0
Serotype 33F at Year 3:I0.0
Serotype 34 at Year 3:I0.0
Serotype 35B at Year 3:I2.7
Serotype 35F at Year 3:I0.0
Serotype 38 at Year 3:I0.0
Serotype clumps at Year 3:I0.0
Serotype Missing/non-viable at Year 3:I0.0
Serotype 3 at Year 1:R0.0
Serotype 6C at Year 1:R0.0
Serotype 7C at Year 1:R0.0
Serotype 9N at Year 1:R0.0
Serotype 10 at Year 1:R0.0
Serotype 11 at Year 1:R0.0
Serotype 12 at Year 1:R0.0
Serotype 12F at Year 1:R0.0
Serotype 13 at Year 1:R0.0
Serotype 15A at Year 1:R2.2
Serotype 15B at Year 1:R0.0
Serotype 15C at Year 1:R0.0
Serotype 15F at Year 1:R0.0
Serotype 16 at Year 1:R0.0
Serotype 17 at Year 1:R0.0
Serotype 19A at Year 1:R12.6
Serotype 19F at Year 1:R0.0
Serotype 20 at Year 1:R0.0
Serotype 21 at Year 1:R0.0
Serotype 22F at Year 1:R0.0
Serotype 23A at Year 1:R0.0
Serotype 23B at Year 1:R0.0
Serotype 31 at Year 1:R0.0
Serotype 33A at Year 1:R0.0
Serotype 33F at Year 1:R0.0
Serotype 34 at Year 1:R0.0
Serotype 35B at Year 1:R0.0
Serotype 35F at Year 1:R0.0
Serotype 38 at Year 1:R0.0
Serotype clumps at Year 1:R0.0
Serotype Missing/non-viable at Year 1:R0.0
Serotype 3 at Year 2:R0.0
Serotype 6C at Year 2:R0.0
Serotype 7C at Year 2:R0.0
Serotype 9N at Year 2:R0.0
Serotype 10 at Year 2:R0.0
Serotype 11 at Year 2:R0.9
Serotype 12 at Year 2:R0.0
Serotype 12F at Year 2:R0.0
Serotype 13 at Year 2:R0.0
Serotype 15A at Year 2:R0.9
Serotype 15B at Year 2:R0.0
Serotype 15C at Year 2:R0.0
Serotype 15F at Year 2:R0.0
Serotype 16 at Year 2:R0.0
Serotype 17 at Year 2:R0.0
Serotype 19A at Year 2:R6.3
Serotype 19F at Year 2:R0.0
Serotype 20 at Year 2:R0.0
Serotype 21 at Year 2:R0.0
Serotype 22F at Year 2:R0.0
Serotype 23A at Year 2:R0.0
Serotype 23B at Year 2:R0.0
Serotype 31 at Year 2:R0.0
Serotype 33A at Year 2:R0.0
Serotype 33F at Year 2:R0.0
Serotype 34 at Year 2:R0.0
Serotype 35B at Year 2:R0.9
Serotype 35F at Year 2:R0.0
Serotype 38 at Year 2:R0.0
Serotype clumps at Year 2:R0.0
Serotype Missing/non-viable at Year 2:R0.0
Serotype 3 at Year 3:R0.0
Serotype 6C at Year 3:R0.0
Serotype 7C at Year 3:R0.0
Serotype 9N at Year 3:R0.0
Serotype 10 at Year 3:R0.0
Serotype 11 at Year 3:R0.0
Serotype 12 at Year 3:R0.0
Serotype 12F at Year 3:R0.0
Serotype 13 at Year 3:R0.0
Serotype 15A at Year 3:R0.9
Serotype 15B at Year 3:R0.0
Serotype 15C at Year 3:R0.0
Serotype 15F at Year 3:R0.0
Serotype 16 at Year 3:R0.0
Serotype 17 at Year 3:R0.0
Serotype 19A at Year 3:R4.5
Serotype 19F at Year 3:R0.9
Serotype 20 at Year 3:R0.0
Serotype 21 at Year 3:R0.0
Serotype 22F at Year 3:R0.0
Serotype 23A at Year 3:R0.0
Serotype 23B at Year 3:R0.0
Serotype 31 at Year 3:R0.0
Serotype 33A at Year 3:R0.0
Serotype 33F at Year 3:R0.0
Serotype 34 at Year 3:R0.0
Serotype 35B at Year 3:R0.9
Serotype 35F at Year 3:R0.0
Serotype 38 at Year 3:R0.0
Serotype clumps at Year 3:R0.0
Serotype Missing/non-viable at Year 3:R0.0
SecondaryAntimicrobial Susceptibility of Streptococcus Pneumoniae Isolates for Erythromycin: Middle Ear Fluid (MEF) Population

Antimicrobial susceptibility of S pneumoniae isolates for erythromycin from MEF samples was categorized as resistant, susceptible or intermediate based on MIC for each serotype at each year of the whole surveillance period. The percentage of S pneumoniae serotypes included 3, 6C, 7C, 9N, 10, 11, 12, 12F, 13, 15A, 15B, 15C, 15F, 16, 17, 19A, 19F, 20, 21, 22F, 23A, 23B, 31, 33A, 33F, 34, 35B, 35F, 38, clumps and missing or non-viable, which were to be computed along with exact 2-sided 95% CI based on the observed proportion of isolates. Missing or non-viable included isolates that were either not sent from an external laboratory, were non-viable or lost on culture prior to sending, or were non-viable on receipt in the central laboratory.'Number of isolates analyzed' signifies total number of isolates that were evaluable for this OM.

Time frame:
Surveillance Year 1, 2, 3
Reported as:
Number · percentage of isolates
Antimicrobial Susceptibility of Streptococcus Pneumoniae Isolates for Erythromycin: Middle Ear Fluid (MEF) Population
percentage of isolatesMEF Population
Serotype 3 at Year 1:S5.9
Serotype 6C at Year 1:S4.4
Serotype 7C at Year 1:S1.5
Serotype 9N at Year 1:S2.2
Serotype 10 at Year 1:S3.0
Serotype 11 at Year 1:S3.0
Serotype 12 at Year 1:S0.7
Serotype 12F at Year 1:S0.0
Serotype 13 at Year 1:S0.0
Serotype 15A at Year 1:S1.5
Serotype 15B at Year 1:S3.0
Serotype 15C at Year 1:S1.5
Serotype 15F at Year 1:S0.0
Serotype 16 at Year 1:S1.5
Serotype 17 at Year 1:S0.0
Serotype 19A at Year 1:S1.5
Serotype 19F at Year 1:S0.7
Serotype 20 at Year 1:S0.0
Serotype 21 at Year 1:S3.0
Serotype 22F at Year 1:S1.5
Serotype 23A at Year 1:S3.0
Serotype 23B at Year 1:S0.7
Serotype 31 at Year 1:S0.7
Serotype 33A at Year 1:S0.0
Serotype 33F at Year 1:S0.7
Serotype 34 at Year 1:S0.0
Serotype 35B at Year 1:S2.2
Serotype 35F at Year 1:S0.0
Serotype 38 at Year 1:S0.7
Serotype clumps at Year 1:S0.7
Serotype Missing/non-viable at Year 1:S0.7
Serotype 3 at Year 2:S5.4
Serotype 6C at Year 2:S2.7
Serotype 7C at Year 2:S0.0
Serotype 9N at Year 2:S0.0
Serotype 10 at Year 2:S0.0
Serotype 11 at Year 2:S3.6
Serotype 12 at Year 2:S0.0
Serotype 12F at Year 2:S0.9
Serotype 13 at Year 2:S0.0
Serotype 15A at Year 2:S0.0
Serotype 15B at Year 2:S1.8
Serotype 15C at Year 2:S0.9
Serotype 15F at Year 2:S0.0
Serotype 16 at Year 2:S2.7
Serotype 17 at Year 2:S1.8
Serotype 19A at Year 2:S3.6
Serotype 19F at Year 2:S0.9
Serotype 20 at Year 2:S0.0
Serotype 21 at Year 2:S9.0
Serotype 22F at Year 2:S0.9
Serotype 23A at Year 2:S3.6
Serotype 23B at Year 2:S5.4
Serotype 31 at Year 2:S1.8
Serotype 33A at Year 2:S0.0
Serotype 33F at Year 2:S0.0
Serotype 34 at Year 2:S0.9
Serotype 35B at Year 2:S3.6
Serotype 35F at Year 2:S0.9
Serotype 38 at Year 2:S0.9
Serotype clumps at Year 2:S0.9
Serotype Missing/non-viable at Year 2:S0.9
Serotype 3 at Year 3:S5.4
Serotype 6C at Year 3:S1.8
Serotype 7C at Year 3:S0.0
Serotype 9N at Year 3:S0.9
Serotype 10 at Year 3:S2.7
Serotype 11 at Year 3:S0.9
Serotype 12 at Year 3:S0.0
Serotype 12F at Year 3:S0.0
Serotype 13 at Year 3:S0.0
Serotype 15A at Year 3:S2.7
Serotype 15B at Year 3:S1.8
Serotype 15C at Year 3:S3.6
Serotype 15F at Year 3:S0.0
Serotype 16 at Year 3:S3.6
Serotype 17 at Year 3:S0.9
Serotype 19A at Year 3:S0.9
Serotype 19F at Year 3:S2.7
Serotype 20 at Year 3:S0.9
Serotype 21 at Year 3:S4.5
Serotype 22F at Year 3:S1.8
Serotype 23A at Year 3:S2.7
Serotype 23B at Year 3:S3.6
Serotype 31 at Year 3:S4.5
Serotype 33A at Year 3:S0.0
Serotype 33F at Year 3:S0.0
Serotype 34 at Year 3:S0.9
Serotype 35B at Year 3:S2.7
Serotype 35F at Year 3:S0.9
Serotype 38 at Year 3:S0.9
Serotype clumps at Year 3:S0.0
Serotype Missing/non-viable at Year 3:S0.9
Serotype 3 at Year 1:I0.0
Serotype 6C at Year 1:I0.0
Serotype 7C at Year 1:I0.0
Serotype 9N at Year 1:I0.0
Serotype 10 at Year 1:I0.0
Serotype 11 at Year 1:I0.7
Serotype 12 at Year 1:I0.0
Serotype 12F at Year 1:I0.0
Serotype 13 at Year 1:I0.7
Serotype 15A at Year 1:I0.0
Serotype 15B at Year 1:I0.0
Serotype 15C at Year 1:I0.7
Serotype 15F at Year 1:I0.0
Serotype 16 at Year 1:I0.0
Serotype 17 at Year 1:I0.0
Serotype 19A at Year 1:I14.1
Serotype 19F at Year 1:I0.7
Serotype 20 at Year 1:I0.0
Serotype 21 at Year 1:I0.0
Serotype 22F at Year 1:I0.0
Serotype 23A at Year 1:I0.0
Serotype 23B at Year 1:I0.0
Serotype 31 at Year 1:I0.7
Serotype 33A at Year 1:I0.0
Serotype 33F at Year 1:I0.0
Serotype 34 at Year 1:I0.0
Serotype 35B at Year 1:I0.0
Serotype 35F at Year 1:I0.0
Serotype 38 at Year 1:I0.0
Serotype clumps at Year 1:I0.0
Serotype Missing/non-viable at Year 1:I0.0
Serotype 3 at Year 2:I0.9
Serotype 6C at Year 2:I0.0
Serotype 7C at Year 2:I0.0
Serotype 9N at Year 2:I0.0
Serotype 10 at Year 2:I0.0
Serotype 11 at Year 2:I0.9
Serotype 12 at Year 2:I0.0
Serotype 12F at Year 2:I0.0
Serotype 13 at Year 2:I0.0
Serotype 15A at Year 2:I0.0
Serotype 15B at Year 2:I2.7
Serotype 15C at Year 2:I0.0
Serotype 15F at Year 2:I0.0
Serotype 16 at Year 2:I0.0
Serotype 17 at Year 2:I0.0
Serotype 19A at Year 2:I12.6
Serotype 19F at Year 2:I0.0
Serotype 20 at Year 2:I0.0
Serotype 21 at Year 2:I0.0
Serotype 22F at Year 2:I0.0
Serotype 23A at Year 2:I0.0
Serotype 23B at Year 2:I0.9
Serotype 31 at Year 2:I0.0
Serotype 33A at Year 2:I0.0
Serotype 33F at Year 2:I0.0
Serotype 34 at Year 2:I0.0
Serotype 35B at Year 2:I0.9
Serotype 35F at Year 2:I0.0
Serotype 38 at Year 2:I0.0
Serotype clumps at Year 2:I0.0
Serotype Missing/non-viable at Year 2:I0.0
Serotype 3 at Year 3:I1.8
Serotype 6C at Year 3:I0.0
Serotype 7C at Year 3:I0.0
Serotype 9N at Year 3:I0.0
Serotype 10 at Year 3:I0.0
Serotype 11 at Year 3:I0.9
Serotype 12 at Year 3:I0.0
Serotype 12F at Year 3:I0.0
Serotype 13 at Year 3:I0.0
Serotype 15A at Year 3:I2.7
Serotype 15B at Year 3:I0.9
Serotype 15C at Year 3:I0.9
Serotype 15F at Year 3:I0.9
Serotype 16 at Year 3:I0.0
Serotype 17 at Year 3:I0.0
Serotype 19A at Year 3:I2.7
Serotype 19F at Year 3:I1.8
Serotype 20 at Year 3:I0.0
Serotype 21 at Year 3:I0.0
Serotype 22F at Year 3:I0.9
Serotype 23A at Year 3:I0.0
Serotype 23B at Year 3:I1.8
Serotype 31 at Year 3:I0.0
Serotype 33A at Year 3:I0.0
Serotype 33F at Year 3:I0.0
Serotype 34 at Year 3:I0.0
Serotype 35B at Year 3:I2.7
Serotype 35F at Year 3:I0.0
Serotype 38 at Year 3:I0.0
Serotype clumps at Year 3:I0.0
Serotype Missing/non-viable at Year 3:I0.0
Serotype 3 at Year 1:R0.0
Serotype 6C at Year 1:R2.2
Serotype 7C at Year 1:R0.0
Serotype 9N at Year 1:R0.0
Serotype 10 at Year 1:R0.0
Serotype 11 at Year 1:R0.0
Serotype 12 at Year 1:R0.0
Serotype 12F at Year 1:R0.0
Serotype 13 at Year 1:R0.0
Serotype 15A at Year 1:R1.5
Serotype 15B at Year 1:R0.7
Serotype 15C at Year 1:R1.5
Serotype 15F at Year 1:R0.0
Serotype 16 at Year 1:R0.0
Serotype 17 at Year 1:R0.0
Serotype 19A at Year 1:R14.8
Serotype 19F at Year 1:R0.7
Serotype 20 at Year 1:R0.0
Serotype 21 at Year 1:R0.0
Serotype 22F at Year 1:R0.0
Serotype 23A at Year 1:R0.0
Serotype 23B at Year 1:R0.0
Serotype 31 at Year 1:R0.7
Serotype 33A at Year 1:R0.7
Serotype 33F at Year 1:R2.2
Serotype 34 at Year 1:R0.0
Serotype 35B at Year 1:R4.4
Serotype 35F at Year 1:R0.0
Serotype 38 at Year 1:R0.0
Serotype clumps at Year 1:R0.0
Serotype Missing/non-viable at Year 1:R0.0
Serotype 3 at Year 2:R0.0
Serotype 6C at Year 2:R0.9
Serotype 7C at Year 2:R0.0
Serotype 9N at Year 2:R0.0
Serotype 10 at Year 2:R0.9
Serotype 11 at Year 2:R2.7
Serotype 12 at Year 2:R0.0
Serotype 12F at Year 2:R0.0
Serotype 13 at Year 2:R0.0
Serotype 15A at Year 2:R0.9
Serotype 15B at Year 2:R0.0
Serotype 15C at Year 2:R1.8
Serotype 15F at Year 2:R0.0
Serotype 16 at Year 2:R0.0
Serotype 17 at Year 2:R0.0
Serotype 19A at Year 2:R6.3
Serotype 19F at Year 2:R0.0
Serotype 20 at Year 2:R0.0
Serotype 21 at Year 2:R0.0
Serotype 22F at Year 2:R0.0
Serotype 23A at Year 2:R0.9
Serotype 23B at Year 2:R0.9
Serotype 31 at Year 2:R0.0
Serotype 33A at Year 2:R0.0
Serotype 33F at Year 2:R0.0
Serotype 34 at Year 2:R0.0
Serotype 35B at Year 2:R9.0
Serotype 35F at Year 2:R0.0
Serotype 38 at Year 2:R0.0
Serotype clumps at Year 2:R0.0
Serotype Missing/non-viable at Year 2:R0.0
Serotype 3 at Year 3:R0.0
Serotype 6C at Year 3:R0.0
Serotype 7C at Year 3:R0.0
Serotype 9N at Year 3:R0.0
Serotype 10 at Year 3:R0.0
Serotype 11 at Year 3:R1.8
Serotype 12 at Year 3:R0.0
Serotype 12F at Year 3:R0.0
Serotype 13 at Year 3:R0.0
Serotype 15A at Year 3:R0.0
Serotype 15B at Year 3:R1.8
Serotype 15C at Year 3:R0.9
Serotype 15F at Year 3:R0.0
Serotype 16 at Year 3:R0.9
Serotype 17 at Year 3:R0.0
Serotype 19A at Year 3:R6.3
Serotype 19F at Year 3:R0.9
Serotype 20 at Year 3:R0.0
Serotype 21 at Year 3:R0.9
Serotype 22F at Year 3:R0.0
Serotype 23A at Year 3:R0.0
Serotype 23B at Year 3:R2.7
Serotype 31 at Year 3:R0.0
Serotype 33A at Year 3:R0.0
Serotype 33F at Year 3:R1.8
Serotype 34 at Year 3:R0.0
Serotype 35B at Year 3:R5.4
Serotype 35F at Year 3:R0.9
Serotype 38 at Year 3:R0.0
Serotype clumps at Year 3:R0.0
Serotype Missing/non-viable at Year 3:R0.9
SecondaryAntimicrobial Susceptibility of Streptococcus Pneumoniae Isolates for Penicillin: Middle Ear Fluid (MEF) Population

Antimicrobial susceptibility of S pneumoniae isolates for penicillin from MEF samples were summarized by providing the range of MICs for penicillin tested and the percentage of the susceptibility interpretation was categorized as resistant, susceptible or intermediate for each serotype, and for each year of the whole surveillance period. The percentage of S pneumoniae serotypes included 3, 6C, 7C, 9N, 10, 11, 12, 12F, 13, 15A, 15B, 15C, 15F, 16, 17, 19 A, 19 F, 20, 21, 22F, 23A, 23B, 31, 33A, 33F, 34, 35B, 35F, 38, clumps and missing or non-viable, which were to be computed along with exact 2-sided 95 % CI based on the observed proportion of isolates. Missing or non-viable included isolates that were either not sent from an external laboratory, were non-viable or lost on culture prior to sending, or were non-viable on receipt in the central laboratory.'Number of isolates analyzed' signifies total number of isolates that were evaluable for this OM.

Time frame:
Surveillance Year 1, 2, 3
Reported as:
Number · percentage of isolates
Antimicrobial Susceptibility of Streptococcus Pneumoniae Isolates for Penicillin: Middle Ear Fluid (MEF) Population
percentage of isolatesMEF Population
Serotype 3 at Year 1:S5.2
Serotype 7C at Year 1:S1.5
Serotype 9N at Year 1:S2.2
Serotype 10 at Year 1:S3.0
Serotype 11 at Year 1:S3.7
Serotype 12 at Year 1:S0.0
Serotype 12F at Year 1:S0.0
Serotype 13 at Year 1:S0.0
Serotype 15A at Year 1:S0.7
Serotype 15B at Year 1:S3.7
Serotype 15C at Year 1:S1.5
Serotype 15F at Year 1:S0.0
Serotype 16 at Year 1:S1.5
Serotype 17 at Year 1:S0.0
Serotype 19A at Year 1:S2.2
Serotype 19F at Year 1:S0.7
Serotype 20 at Year 1:S0.0
Serotype 21 at Year 1:S3.0
Serotype 22F at Year 1:S1.5
Serotype 23A at Year 1:S0.0
Serotype 23B at Year 1:S0.7
Serotype 31 at Year 1:S2.2
Serotype 33A at Year 1:S0.7
Serotype 33F at Year 1:S1.5
Serotype 34 at Year 1:S0.0
Serotype 35B at Year 1:S0.0
Serotype 35F at Year 1:S0.0
Serotype 38 at Year 1:S0.7
Serotype clumps at Year 1:S0.7
Serotype Missing/non-viable at Year 1:S1.5
Serotype 3 at Year 2:S6.3
Serotype 6C at Year 2:S0.9
Serotype 7C at Year 2:S0.0
Serotype 9N at Year 2:S0.0
Serotype 10 at Year 2:S0.9
Serotype 11 at Year 2:S6.3
Serotype 12 at Year 2:S0.0
Serotype 12F at Year 2:S0.9
Serotype 13 at Year 2:S0.0
Serotype 15A at Year 2:S0.0
Serotype 15B at Year 2:S1.8
Serotype 15C at Year 2:S1.8
Serotype 15F at Year 2:S0.0
Serotype 16 at Year 2:S1.8
Serotype 17 at Year 2:S0.9
Serotype 19A at Year 2:S1.8
Serotype 19F at Year 2:S0.9
Serotype 20 at Year 2:S0.0
Serotype 21 at Year 2:S8.1
Serotype 22F at Year 2:S0.9
Serotype 23A at Year 2:S0.0
Serotype 23B at Year 2:S2.7
Serotype 31 at Year 2:S1.8
Serotype 33A at Year 2:S0.0
Serotype 33F at Year 2:S0.0
Serotype 34 at Year 2:S0.9
Serotype 35B at Year 2:S0.9
Serotype 35F at Year 2:S0.9
Serotype 38 at Year 2:S0.9
Serotype clumps at Year 2:S0.9
Serotype Missing/non-viable at Year 2:S0.9
Serotype 3 at Year 3:S6.3
Serotype 6C at Year 3:S1.8
Serotype 7C at Year 3:S0.0
Serotype 9N at Year 3:S0.9
Serotype 10 at Year 3:S2.7
Serotype 11 at Year 3:S3.6
Serotype 12 at Year 3:S0.0
Serotype 12F at Year 3:S0.0
Serotype 13 at Year 3:S0.0
Serotype 15A at Year 3:S3.6
Serotype 15B at Year 3:S1.8
Serotype 15C at Year 3:S2.7
Serotype 15F at Year 3:S0.0
Serotype 16 at Year 3:S4.5
Serotype 17 at Year 3:S0.9
Serotype 19A at Year 3:S0.9
Serotype 19F at Year 3:S3.6
Serotype 20 at Year 3:S0.9
Serotype 21 at Year 3:S5.4
Serotype 22F at Year 3:S2.7
Serotype 23A at Year 3:S0.9
Serotype 23B at Year 3:S6.3
Serotype 31 at Year 3:S3.6
Serotype 33A at Year 3:S0.0
Serotype 33F at Year 3:S0.9
Serotype 34 at Year 3:S0.9
Serotype 35B at Year 3:S0.0
Serotype 35F at Year 3:S0.0
Serotype 38 at Year 3:S0.9
Serotype clumps at Year 3:S0.0
Serotype Missing/non-viable at Year 3:S0.0
Serotype 6C at Year 1:S2.2
Serotype 3 at Year 1:I0.7
Serotype 6C at Year 1:I3.7
Serotype 7C at Year 1:I0.0
Serotype 9N at Year 1:I0.0
Serotype 10 at Year 1:I0.0
Serotype 11 at Year 1:I0.0
Serotype 12 at Year 1:I0.7
Serotype 12F at Year 1:I0.0
Serotype 13 at Year 1:I0.7
Serotype 15A at Year 1:I3.0
Serotype 15B at Year 1:I0.7
Serotype 15C at Year 1:I2.2
Serotype 15F at Year 1:I0.0
Serotype 16 at Year 1:I0.0
Serotype 17 at Year 1:I0.0
Serotype 19A at Year 1:I2.2
Serotype 19F at Year 1:I0.7
Serotype 20 at Year 1:I0.0
Serotype 21 at Year 1:I0.0
Serotype 22F at Year 1:I0.0
Serotype 23A at Year 1:I3.0
Serotype 23B at Year 1:I0.7
Serotype 31 at Year 1:I0.0
Serotype 33A at Year 1:I0.0
Serotype 33F at Year 1:I1.5
Serotype 34 at Year 1:I0.0
Serotype 35B at Year 1:I5.2
Serotype 35F at Year 1:I0.0
Serotype 38 at Year 1:I0.0
Serotype clumps at Year 1:I0.0
Serotype Missing/non-viable at Year 1:I0.0
Serotype 3 at Year 2:I0.0
Serotype 6C at Year 2:I2.7
Serotype 7C at Year 2:I0.0
Serotype 9N at Year 2:I0.0
Serotype 10 at Year 2:I0.0
Serotype 11 at Year 2:I0.0
Serotype 12 at Year 2:I0.0
Serotype 12F at Year 2:I0.0
Serotype 13 at Year 2:I0.0
Serotype 15A at Year 2:I0.9
Serotype 15B at Year 2:I2.7
Serotype 15C at Year 2:I0.9
Serotype 15F at Year 2:I0.0
Serotype 16 at Year 2:I0.9
Serotype 17 at Year 2:I0.9
Serotype 19A at Year 2:I1.8
Serotype 19F at Year 2:I0.0
Serotype 20 at Year 2:I0.0
Serotype 21 at Year 2:I0.9
Serotype 22F at Year 2:I0.0
Serotype 23A at Year 2:I4.5
Serotype 23B at Year 2:I3.6
Serotype 31 at Year 2:I0.0
Serotype 33A at Year 2:I0.0
Serotype 33F at Year 2:I0.0
Serotype 34 at Year 2:I0.0
Serotype 35B at Year 2:I9.9
Serotype 35F at Year 2:I0.0
Serotype 38 at Year 2:I0.0
Serotype clumps at Year 2:I0.0
Serotype Missing/non-viable at Year 2:I0.0
Serotype 3 at Year 3:I0.0
Serotype 6C at Year 3:I0.0
Serotype 7C at Year 3:I0.0
Serotype 9N at Year 3:I0.0
Serotype 10 at Year 3:I0.0
Serotype 11 at Year 3:I0.0
Serotype 12 at Year 3:I0.0
Serotype 12F at Year 3:I0.0
Serotype 13 at Year 3:I0.0
Serotype 15A at Year 3:I1.8
Serotype 15B at Year 3:I2.7
Serotype 15C at Year 3:I2.7
Serotype 15F at Year 3:I0.9
Serotype 16 at Year 3:I0.0
Serotype 17 at Year 3:I0.0
Serotype 19A at Year 3:I0.0
Serotype 19F at Year 3:I0.0
Serotype 20 at Year 3:I0.0
Serotype 21 at Year 3:I0.0
Serotype 22F at Year 3:I0.0
Serotype 23A at Year 3:I1.8
Serotype 23B at Year 3:I1.8
Serotype 31 at Year 3:I0.9
Serotype 33A at Year 3:I0.0
Serotype 33F at Year 3:I0.9
Serotype 34 at Year 3:I0.0
Serotype 35B at Year 3:I6.3
Serotype 35F at Year 3:I0.9
Serotype 38 at Year 3:I0.0
Serotype clumps at Year 3:I0.0
Serotype Missing/non-viable at Year 3:I1.8
Serotype 3 at Year 1:R0.0
Serotype 6C at Year 1:R0.7
Serotype 7C at Year 1:R0.0
Serotype 9N at Year 1:R0.0
Serotype 10 at Year 1:R0.0
Serotype 11 at Year 1:R0.0
Serotype 12 at Year 1:R0.0
Serotype 12F at Year 1:R0.0
Serotype 13 at Year 1:R0.0
Serotype 15A at Year 1:R0.0
Serotype 15B at Year 1:R0.0
Serotype 15C at Year 1:R0.0
Serotype 15F at Year 1:R0.0
Serotype 16 at Year 1:R0.0
Serotype 17 at Year 1:R0.0
Serotype 19A at Year 1:R25.9
Serotype 19F at Year 1:R0.7
Serotype 20 at Year 1:R0.0
Serotype 21 at Year 1:R0.0
Serotype 22F at Year 1:R0.0
Serotype 23A at Year 1:R0.0
Serotype 23B at Year 1:R0.0
Serotype 31 at Year 1:R0.0
Serotype 33A at Year 1:R0.0
Serotype 33F at Year 1:R0.0
Serotype 34 at Year 1:R0.0
Serotype 35B at Year 1:R1.5
Serotype 35F at Year 1:R0.0
Serotype 38 at Year 1:R0.0
Serotype clumps at Year 1:R0.7
Serotype Missing/non-viable at Year 1:R0.0
Serotype 3 at Year 2:R0.0
Serotype 6C at Year 2:R0.0
Serotype 7C at Year 2:R0.0
Serotype 9N at Year 2:R0.0
Serotype 10 at Year 2:R0.0
Serotype 11 at Year 2:R0.9
Serotype 12 at Year 2:R0.0
Serotype 12F at Year 2:R0.0
Serotype 13 at Year 2:R0.0
Serotype 15A at Year 2:R0.0
Serotype 15B at Year 2:R0.0
Serotype 15C at Year 2:R0.0
Serotype 15F at Year 2:R0.0
Serotype 16 at Year 2:R0.0
Serotype 17 at Year 2:R0.0
Serotype 19A at Year 2:R18.9
Serotype 19F at Year 2:R0.0
Serotype 20 at Year 2:R0.0
Serotype 21 at Year 2:R0.0
Serotype 22F at Year 2:R0.0
Serotype 23A at Year 2:R0.0
Serotype 23B at Year 2:R0.9
Serotype 31 at Year 2:R0.0
Serotype 33A at Year 2:R0.0
Serotype 33F at Year 2:R0.0
Serotype 34 at Year 2:R0.0
Serotype 35B at Year 2:R1.8
Serotype 35F at Year 2:R0.0
Serotype 38 at Year 2:R0.0
Serotype clumps at Year 2:R0.0
Serotype Missing/non-viable at Year 2:R0.0
Serotype 3 at Year 3:R0.9
Serotype 6C at Year 3:R0.0
Serotype 7C at Year 3:R0.0
Serotype 9N at Year 3:R0.0
Serotype 10 at Year 3:R0.0
Serotype 11 at Year 3:R0.0
Serotype 12 at Year 3:R0.0
Serotype 12F at Year 3:R0.0
Serotype 13 at Year 3:R0.0
Serotype 15A at Year 3:R0.9
Serotype 15B at Year 3:R0.0
Serotype 15C at Year 3:R0.0
Serotype 15F at Year 3:R0.0
Serotype 16 at Year 3:R0.0
Serotype 17 at Year 3:R0.0
Serotype 19A at Year 3:R9.0
Serotype 19F at Year 3:R1.8
Serotype 20 at Year 3:R0.0
Serotype 21 at Year 3:R0.0
Serotype 22F at Year 3:R0.0
Serotype 23A at Year 3:R0.0
Serotype 23B at Year 3:R0.0
Serotype 31 at Year 3:R0.0
Serotype 33A at Year 3:R0.0
Serotype 33F at Year 3:R0.0
Serotype 34 at Year 3:R0.0
Serotype 35B at Year 3:R2.7
Serotype 35F at Year 3:R0.0
Serotype 38 at Year 3:R0.0
Serotype clumps at Year 3:R0.0
Serotype Missing/non-viable at Year 3:R0.0
SecondaryAntimicrobial Susceptibility of Streptococcus Pneumoniae Isolates for Trimethoprim/Sulfamethoxazole (TMP/S): Middle Ear Fluid (MEF) Population

Antimicrobial susceptibility of S pneumoniae isolates for TMP/S from MEF samples was categorized as resistant, susceptible or intermediate based on MIC for each serotype at each year of the whole surveillance period. The percentage of S pneumoniae serotypes included 3, 6C, 7C, 9N, 10, 11, 12, 12F, 13, 15A, 15B, 15C, 15F, 16, 17, 19A, 19F, 20, 21, 22F, 23A, 23B, 31, 33A, 33F, 34, 35B, 35F, 38, clumps and missing or non-viable, which were to be computed along with exact 2-sided 95% CI based on the observed proportion of isolates. Missing or non-viable included isolates that were either not sent from an external laboratory, were non-viable or lost on culture prior to sending, or were non-viable on receipt in the central laboratory.'Number of isolates analyzed' signifies total number of isolates that were evaluable for this OM.

Time frame:
Surveillance Year 1, 2, 3
Reported as:
Number · percentage of isolates
Antimicrobial Susceptibility of Streptococcus Pneumoniae Isolates for Trimethoprim/Sulfamethoxazole (TMP/S): Middle Ear Fluid (MEF) Population
percentage of isolatesMEF Population
Serotype 3 at Year 1:S3.0
Serotype 6C at Year 1:S0.7
Serotype 7C at Year 1:S1.5
Serotype 9N at Year 1:S1.5
Serotype 10 at Year 1:S0.7
Serotype 11 at Year 1:S2.2
Serotype 12 at Year 1:S0.0
Serotype 12F at Year 1:S0.0
Serotype 13 at Year 1:S0.7
Serotype 15A at Year 1:S0.0
Serotype 15B at Year 1:S1.5
Serotype 15C at Year 1:S0.0
Serotype 15F at Year 1:S0.0
Serotype 16 at Year 1:S1.5
Serotype 17 at Year 1:S0.0
Serotype 19A at Year 1:S0.7
Serotype 19F at Year 1:S0.7
Serotype 20 at Year 1:S0.0
Serotype 21 at Year 1:S1.5
Serotype 22F at Year 1:S0.7
Serotype 23A at Year 1:S0.7
Serotype 23B at Year 1:S0.0
Serotype 31 at Year 1:S0.7
Serotype 33A at Year 1:S0.0
Serotype 33F at Year 1:S0.7
Serotype 34 at Year 1:S0.0
Serotype 35B at Year 1:S0.7
Serotype 35F at Year 1:S0.0
Serotype 38 at Year 1:S0.7
Serotype clumps at Year 1:S0.7
Serotype Missing/non-viable at Year 1:S0.7
Serotype 3 at Year 2:S1.8
Serotype 6C at Year 2:S0.9
Serotype 7C at Year 2:S0.0
Serotype 9N at Year 2:S0.0
Serotype 10 at Year 2:S0.0
Serotype 11 at Year 2:S3.6
Serotype 12 at Year 2:S0.0
Serotype 12F at Year 2:S0.0
Serotype 13 at Year 2:S0.0
Serotype 15A at Year 2:S0.0
Serotype 15B at Year 2:S1.8
Serotype 15C at Year 2:S0.0
Serotype 15F at Year 2:S0.0
Serotype 16 at Year 2:S0.9
Serotype 17 at Year 2:S0.0
Serotype 19A at Year 2:S1.8
Serotype 19F at Year 2:S0.0
Serotype 20 at Year 2:S0.0
Serotype 21 at Year 2:S3.6
Serotype 22F at Year 2:S0.9
Serotype 23A at Year 2:S0.9
Serotype 23B at Year 2:S0.9
Serotype 31 at Year 2:S0.0
Serotype 33A at Year 2:S0.0
Serotype 33F at Year 2:S0.0
Serotype 34 at Year 2:S0.0
Serotype 35B at Year 2:S2.7
Serotype 35F at Year 2:S0.0
Serotype 38 at Year 2:S0.0
Serotype clumps at Year 2:S0.9
Serotype Missing/non-viable at Year 2:S0.0
Serotype 3 at Year 3:S2.7
Serotype 6C at Year 3:S1.8
Serotype 7C at Year 3:S0.0
Serotype 9N at Year 3:S0.0
Serotype 10 at Year 3:S0.0
Serotype 11 at Year 3:S0.9
Serotype 12 at Year 3:S0.0
Serotype 12F at Year 3:S0.0
Serotype 13 at Year 3:S0.0
Serotype 15A at Year 3:S1.8
Serotype 15B at Year 3:S0.0
Serotype 15C at Year 3:S2.7
Serotype 15F at Year 3:S0.0
Serotype 16 at Year 3:S0.9
Serotype 17 at Year 3:S0.0
Serotype 19A at Year 3:S0.9
Serotype 19F at Year 3:S0.9
Serotype 20 at Year 3:S0.0
Serotype 21 at Year 3:S3.6
Serotype 22F at Year 3:S2.7
Serotype 23A at Year 3:S0.0
Serotype 23B at Year 3:S1.8
Serotype 31 at Year 3:S1.8
Serotype 33A at Year 3:S0.0
Serotype 33F at Year 3:S0.0
Serotype 34 at Year 3:S0.0
Serotype 35B at Year 3:S0.9
Serotype 35F at Year 3:S0.9
Serotype 38 at Year 3:S0.0
Serotype clumps at Year 3:S0.0
Serotype Missing/non-viable at Year 3:S0.0
Serotype 3 at Year 1:I0.0
Serotype 6C at Year 1:I1.5
Serotype 7C at Year 1:I0.0
Serotype 9N at Year 1:I0.0
Serotype 10 at Year 1:I0.0
Serotype 11 at Year 1:I0.0
Serotype 12 at Year 1:I0.0
Serotype 12F at Year 1:I0.0
Serotype 13 at Year 1:I0.0
Serotype 15A at Year 1:I0.0
Serotype 15B at Year 1:I0.0
Serotype 15C at Year 1:I0.7
Serotype 15F at Year 1:I0.0
Serotype 16 at Year 1:I0.0
Serotype 17 at Year 1:I0.0
Serotype 19A at Year 1:I14.1
Serotype 19F at Year 1:I0.7
Serotype 20 at Year 1:I0.0
Serotype 21 at Year 1:I0.0
Serotype 22F at Year 1:I0.7
Serotype 23A at Year 1:I0.0
Serotype 23B at Year 1:I0.0
Serotype 31 at Year 1:I0.0
Serotype 33A at Year 1:I0.0
Serotype 33F at Year 1:I0.0
Serotype 34 at Year 1:I0.0
Serotype 35B at Year 1:I0.0
Serotype 35F at Year 1:I0.0
Serotype 38 at Year 1:I0.0
Serotype clumps at Year 1:I0.0
Serotype Missing/non-viable at Year 1:I0.0
Serotype 3 at Year 2:I0.0
Serotype 6C at Year 2:I0.0
Serotype 7C at Year 2:I0.0
Serotype 9N at Year 2:I0.0
Serotype 10 at Year 2:I0.0
Serotype 11 at Year 2:I0.9
Serotype 12 at Year 2:I0.0
Serotype 12F at Year 2:I0.0
Serotype 13 at Year 2:I0.0
Serotype 15A at Year 2:I0.0
Serotype 15B at Year 2:I1.8
Serotype 15C at Year 2:I0.0
Serotype 15F at Year 2:I0.0
Serotype 16 at Year 2:I0.0
Serotype 17 at Year 2:I0.0
Serotype 19A at Year 2:I12.6
Serotype 19F at Year 2:I0.0
Serotype 20 at Year 2:I0.0
Serotype 21 at Year 2:I0.0
Serotype 22F at Year 2:I0.0
Serotype 23A at Year 2:I0.0
Serotype 23B at Year 2:I0.9
Serotype 31 at Year 2:I0.0
Serotype 33A at Year 2:I0.0
Serotype 33F at Year 2:I0.0
Serotype 34 at Year 2:I0.0
Serotype 35B at Year 2:I0.0
Serotype 35F at Year 2:I0.0
Serotype 38 at Year 2:I0.0
Serotype clumps at Year 2:I0.0
Serotype Missing/non-viable at Year 2:I0.0
Serotype 3 at Year 3:I0.9
Serotype 6C at Year 3:I0.0
Serotype 7C at Year 3:I0.0
Serotype 9N at Year 3:I0.0
Serotype 10 at Year 3:I0.0
Serotype 11 at Year 3:I0.9
Serotype 12 at Year 3:I0.0
Serotype 12F at Year 3:I0.0
Serotype 13 at Year 3:I0.0
Serotype 15A at Year 3:I1.8
Serotype 15B at Year 3:I0.9
Serotype 15C at Year 3:I0.9
Serotype 15F at Year 3:I0.9
Serotype 16 at Year 3:I0.0
Serotype 17 at Year 3:I0.0
Serotype 19A at Year 3:I2.7
Serotype 19F at Year 3:I2.7
Serotype 20 at Year 3:I0.0
Serotype 21 at Year 3:I0.0
Serotype 22F at Year 3:I0.0
Serotype 23A at Year 3:I0.0
Serotype 23B at Year 3:I0.0
Serotype 31 at Year 3:I0.0
Serotype 33A at Year 3:I0.0
Serotype 33F at Year 3:I0.0
Serotype 34 at Year 3:I0.9
Serotype 35B at Year 3:I0.9
Serotype 35F at Year 3:I0.0
Serotype 38 at Year 3:I0.0
Serotype clumps at Year 3:I0.0
Serotype Missing/non-viable at Year 3:I0.0
Serotype 3 at Year 1:R3.0
Serotype 6C at Year 1:R4.4
Serotype 7C at Year 1:R0.0
Serotype 9N at Year 1:R0.7
Serotype 10 at Year 1:R1.5
Serotype 11 at Year 1:R1.5
Serotype 12 at Year 1:R0.7
Serotype 12F at Year 1:R0.0
Serotype 13 at Year 1:R0.0
Serotype 15A at Year 1:R3.7
Serotype 15B at Year 1:R2.2
Serotype 15C at Year 1:R3.0
Serotype 15F at Year 1:R0.0
Serotype 16 at Year 1:R0.0
Serotype 17 at Year 1:R0.0
Serotype 19A at Year 1:R15.6
Serotype 19F at Year 1:R0.7
Serotype 20 at Year 1:R0.0
Serotype 21 at Year 1:R1.5
Serotype 22F at Year 1:R0.0
Serotype 23A at Year 1:R2.2
Serotype 23B at Year 1:R0.7
Serotype 31 at Year 1:R1.5
Serotype 33A at Year 1:R0.7
Serotype 33F at Year 1:R2.2
Serotype 34 at Year 1:R0.0
Serotype 35B at Year 1:R5.9
Serotype 35F at Year 1:R0.0
Serotype 38 at Year 1:R0.0
Serotype clumps at Year 1:R0.0
Serotype Missing/non-viable at Year 1:R0.0
Serotype 3 at Year 2:R4.5
Serotype 6C at Year 2:R2.7
Serotype 7C at Year 2:R0.0
Serotype 9N at Year 2:R0.0
Serotype 10 at Year 2:R0.9
Serotype 11 at Year 2:R2.7
Serotype 12 at Year 2:R0.0
Serotype 12F at Year 2:R0.9
Serotype 13 at Year 2:R0.0
Serotype 15A at Year 2:R0.9
Serotype 15B at Year 2:R0.9
Serotype 15C at Year 2:R2.7
Serotype 15F at Year 2:R0.0
Serotype 16 at Year 2:R1.8
Serotype 17 at Year 2:R1.8
Serotype 19A at Year 2:R8.1
Serotype 19F at Year 2:R0.9
Serotype 20 at Year 2:R0.0
Serotype 21 at Year 2:R4.5
Serotype 22F at Year 2:R0.0
Serotype 23A at Year 2:R3.6
Serotype 23B at Year 2:R5.4
Serotype 31 at Year 2:R1.8
Serotype 33A at Year 2:R0.0
Serotype 33F at Year 2:R0.0
Serotype 34 at Year 2:R0.9
Serotype 35B at Year 2:R9.9
Serotype 35F at Year 2:R0.9
Serotype 38 at Year 2:R0.9
Serotype clumps at Year 2:R0.0
Serotype Missing/non-viable at Year 2:R0.9
Serotype 3 at Year 3:R3.6
Serotype 6C at Year 3:R0.0
Serotype 7C at Year 3:R0.0
Serotype 9N at Year 3:R0.9
Serotype 10 at Year 3:R2.7
Serotype 11 at Year 3:R1.8
Serotype 12 at Year 3:R0.0
Serotype 12F at Year 3:R0.0
Serotype 13 at Year 3:R0.0
Serotype 15A at Year 3:R2.7
Serotype 15B at Year 3:R3.6
Serotype 15C at Year 3:R1.8
Serotype 15F at Year 3:R0.0
Serotype 16 at Year 3:R3.6
Serotype 17 at Year 3:R0.9
Serotype 19A at Year 3:R6.3
Serotype 19F at Year 3:R1.8
Serotype 20 at Year 3:R0.9
Serotype 21 at Year 3:R1.8
Serotype 22F at Year 3:R0.0
Serotype 23A at Year 3:R2.7
Serotype 23B at Year 3:R6.3
Serotype 31 at Year 3:R2.7
Serotype 33A at Year 3:R0.0
Serotype 33F at Year 3:R1.8
Serotype 34 at Year 3:R0.0
Serotype 35B at Year 3:R9.0
Serotype 35F at Year 3:R0.9
Serotype 38 at Year 3:R0.9
Serotype clumps at Year 3:R0.0
Serotype Missing/non-viable at Year 3:R1.8
SecondaryAntimicrobial Susceptibility of Streptococcus Pneumoniae Isolates for Ceftriaxone: Mastoid Population

Antimicrobial susceptibility of S pneumoniae isolates for ceftriaxone from mastoid samples was categorized as resistant, susceptible or intermediate based on MIC for each serotype at each year of the whole surveillance period. The percentage of S pneumoniae serotypes included 3, 12, 15A, 15B, 15F, 19A, 19F, 21, 22F, 23A, 38, which were to be computed along with exact 2-sided 95% CI based on the observed proportion of isolates. 'Number of isolates analyzed' signifies total number of isolates that were evaluable for this OM.

Time frame:
Surveillance Year 1, 2, 3
Reported as:
Number · percentage of isolates
Antimicrobial Susceptibility of Streptococcus Pneumoniae Isolates for Ceftriaxone: Mastoid Population
percentage of isolatesMastoid Population
Serotype 3 at Year 1:S0.0
Serotype 12 at Year 1:S5.6
Serotype 15A at Year 1:S5.6
Serotype 15B at Year 1:S5.6
Serotype 15F at Year 1:S0.0
Serotype 19A at Year 1:S27.8
Serotype 19F at Year 1:S11.1
Serotype 21 at Year 1:S0.0
Serotype 22F at Year 1:S11.1
Serotype 23A at Year 1:S5.6
Serotype 38 at Year 1:S5.6
Serotype 3 at Year 2:S28.6
Serotype 12 at Year 2:S0.0
Serotype 15A at Year 2:S0.0
Serotype 15B at Year 2:S0.0
Serotype 15F at Year 2:S0.0
Serotype 19A at Year 2:S57.1
Serotype 19F at Year 2:S0.0
Serotype 21 at Year 2:S0.0
Serotype 22F at Year 2:S0.0
Serotype 23A at Year 2:S0.0
Serotype 38 at Year 2:S0.0
Serotype 3 at Year 3:S44.4
Serotype 12 at Year 3:S0.0
Serotype 15A at Year 3:S0.0
Serotype 15B at Year 3:S0.0
Serotype 15F at Year 3:S0.0
Serotype 19A at Year 3:S0.0
Serotype 19F at Year 3:S11.1
Serotype 21 at Year 3:S0.0
Serotype 22F at Year 3:S0.0
Serotype 23A at Year 3:S0.0
Serotype 38 at Year 3:S0.0
Serotype 3 at Year 1:I0.0
Serotype 12 at Year 1:I0.0
Serotype 15A at Year 1:I0.0
Serotype 15B at Year 1:I0.0
Serotype 15F at Year 1:I0.0
Serotype 19A at Year 1:I0.0
Serotype 19F at Year 1:I0.0
Serotype 21 at Year 1:I0.0
Serotype 22F at Year 1:I0.0
Serotype 23A at Year 1:I0.0
Serotype 38 at Year 1:I0.0
Serotype 3 at Year 2:I0.0
Serotype 12 at Year 2:I0.0
Serotype 15A at Year 2:I0.0
Serotype 15B at Year 2:I0.0
Serotype 15F at Year 2:I0.0
Serotype 19A at Year 2:I0.0
Serotype 19F at Year 2:I0.0
Serotype 21 at Year 2:I0.0
Serotype 22F at Year 2:I0.0
Serotype 23A at Year 2:I0.0
Serotype 38 at Year 2:I0.0
Serotype 3 at Year 3:I0.0
Serotype 12 at Year 3:I0.0
Serotype 15A at Year 3:I0.0
Serotype 15B at Year 3:I0.0
Serotype 15F at Year 3:I0.0
Serotype 19A at Year 3:I0.0
Serotype 19F at Year 3:I0.0
Serotype 21 at Year 3:I0.0
Serotype 22F at Year 3:I0.0
Serotype 23A at Year 3:I0.0
Serotype 38 at Year 3:I0.0
Serotype 3 at Year 1:R0.0
Serotype 12 at Year 1:R0.0
Serotype 15A at Year 1:R0.0
Serotype 15B at Year 1:R0.0
Serotype 15F at Year 1:R0.0
Serotype 19A at Year 1:R5.6
Serotype 19F at Year 1:R0.0
Serotype 21 at Year 1:R0.0
Serotype 22F at Year 1:R0.0
Serotype 23A at Year 1:R0.0
Serotype 38 at Year 1:R0.0
Serotype 3 at Year 2:R0.0
Serotype 12 at Year 2:R0.0
Serotype 15A at Year 2:R0.0
Serotype 15B at Year 2:R0.0
Serotype 15F at Year 2:R0.0
Serotype 19A at Year 2:R0.0
Serotype 19F at Year 2:R0.0
Serotype 21 at Year 2:R0.0
Serotype 22F at Year 2:R0.0
Serotype 23A at Year 2:R0.0
Serotype 38 at Year 2:R0.0
Serotype 3 at Year 3:R0.0
Serotype 12 at Year 3:R0.0
Serotype 15A at Year 3:R0.0
Serotype 15B at Year 3:R0.0
Serotype 15F at Year 3:R0.0
Serotype 19A at Year 3:R11.1
Serotype 19F at Year 3:R0.0
Serotype 21 at Year 3:R0.0
Serotype 22F at Year 3:R0.0
Serotype 23A at Year 3:R0.0
Serotype 38 at Year 3:R0.0
SecondaryAntimicrobial Susceptibility of Streptococcus Pneumoniae Isolates for Clindamycin: Mastoid Population

Antimicrobial susceptibility of S pneumoniae isolates for clindamycin from mastoid samples was categorized as resistant, susceptible or intermediate based on MIC for each serotype at each year of the whole surveillance period. The percentage of S pneumoniae serotypes included 3, 12, 15A, 15B, 15F, 19A, 19F, 21, 22F, 23A, 38, which were to be computed along with exact 2-sided 95% CI based on the observed proportion of isolates. 'Number of isolates analyzed' signifies total number of isolates that were evaluable for this OM.

Time frame:
Surveillance Year 1, 2, 3
Reported as:
Number · percentage of isolates
Antimicrobial Susceptibility of Streptococcus Pneumoniae Isolates for Clindamycin: Mastoid Population
percentage of isolatesMastoid Population
Serotype 3 at Year 1:S0.0
Serotype 15F at Year 1:S0.0
Serotype 19A at Year 1:S5.6
Serotype 19F at Year 1:S0.0
Serotype 21 at Year 1:S0.0
Serotype 22F at Year 1:S5.6
Serotype 23A at Year 1:S5.6
Serotype 38 at Year 1:S5.6
Serotype 3 at Year 2:S28.6
Serotype 12 at Year 2:S0.0
Serotype 15A at Year 2:S0.0
Serotype 15B at Year 2:S0.0
Serotype 15F at Year 2:S0.0
Serotype 19A at Year 2:S28.6
Serotype 19F at Year 2:S0.0
Serotype 21 at Year 2:S0.0
Serotype 22F at Year 2:S0.0
Serotype 23A at Year 2:S0.0
Serotype 38 at Year 2:S0.0
Serotype 3 at Year 3:S22.2
Serotype 12 at Year 3:S0.0
Serotype 15A at Year 3:S0.0
Serotype 15B at Year 3:S0.0
Serotype 15F at Year 3:S0.0
Serotype 19A at Year 3:S0.0
Serotype 19F at Year 3:S11.1
Serotype 21 at Year 3:S0.0
Serotype 22F at Year 3:S0.0
Serotype 23A at Year 3:S0.0
Serotype 38 at Year 3:S0.0
Serotype 3 at Year 1:I0.0
Serotype 12 at Year 1:I0.0
Serotype 15A at Year 1:I0.0
Serotype 15B at Year 1:I0.0
Serotype 15F at Year 1:I0.0
Serotype 19A at Year 1:I5.6
Serotype 19F at Year 1:I0.0
Serotype 21 at Year 1:I0.0
Serotype 22F at Year 1:I0.0
Serotype 23A at Year 1:I0.0
Serotype 38 at Year 1:I0.0
Serotype 3 at Year 2:I0.0
Serotype 12 at Year 2:I0.0
Serotype 15A at Year 2:I0.0
Serotype 15B at Year 2:I0.0
Serotype 15F at Year 2:I0.0
Serotype 19A at Year 2:I14.3
Serotype 19F at Year 2:I0.0
Serotype 21 at Year 2:I0.0
Serotype 22F at Year 2:I0.0
Serotype 23A at Year 2:I0.0
Serotype 38 at Year 2:I0.0
Serotype 3 at Year 3:I0.0
Serotype 12 at Year 3:I0.0
Serotype 15A at Year 3:I0.0
Serotype 15B at Year 3:I0.0
Serotype 15F at Year 3:I0.0
Serotype 19A at Year 3:I0.0
Serotype 19F at Year 3:I0.0
Serotype 21 at Year 3:I0.0
Serotype 22F at Year 3:I0.0
Serotype 23A at Year 3:I0.0
Serotype 38 at Year 3:I0.0
Serotype 3 at Year 1:R0.0
Serotype 12 at Year 1:R0.0
Serotype 15A at Year 1:R5.6
Serotype 15B at Year 1:R0.0
Serotype 15F at Year 1:R0.0
Serotype 19A at Year 1:R22.2
Serotype 19F at Year 1:R5.6
Serotype 21 at Year 1:R0.0
Serotype 22F at Year 1:R0.0
Serotype 23A at Year 1:R0.0
Serotype 38 at Year 1:R0.0
Serotype 3 at Year 2:R0.0
Serotype 12 at Year 2:R0.0
Serotype 15A at Year 2:R0.0
Serotype 15B at Year 2:R0.0
Serotype 15F at Year 2:R0.0
Serotype 19A at Year 2:R28.6
Serotype 19F at Year 2:R0.0
Serotype 21 at Year 2:R0.0
Serotype 22F at Year 2:R0.0
Serotype 23A at Year 2:R0.0
Serotype 38 at Year 2:R0.0
Serotype 3 at Year 3:R11.1
Serotype 12 at Year 3:R0.0
Serotype 15A at Year 3:R0.0
Serotype 15B at Year 3:R0.0
Serotype 15F at Year 3:R0.0
Serotype 19A at Year 3:R11.1
Serotype 19F at Year 3:R0.0
Serotype 21 at Year 3:R0.0
Serotype 22F at Year 3:R0.0
Serotype 23A at Year 3:R0.0
Serotype 38 at Year 3:R0.0
Serotype 12 at Year 1:S5.6
Serotype 15A at Year 1:S0.0
Serotype 15B at Year 1:S5.6
SecondaryAntimicrobial Susceptibility of Streptococcus Pneumoniae Isolates for Erythromycin: Mastoid Population

Antimicrobial susceptibility of S pneumoniae isolates for erythromycin from mastoid samples was categorized as resistant, susceptible or intermediate based on MIC for each serotype at each year of the whole surveillance period. The percentage of S pneumoniae serotypes included 3, 12, 15A, 15B, 15F, 19A, 19F, 21, 22F, 23A, 38, which were to be computed along with exact 2-sided 95% CI based on the observed proportion of isolates. 'Number of isolates analyzed' signifies total number of isolates that were evaluable for this OM.

Time frame:
Surveillance Year 1, 2, 3
Reported as:
Number · percentage of isolates
Antimicrobial Susceptibility of Streptococcus Pneumoniae Isolates for Erythromycin: Mastoid Population
percentage of isolatesMastoid Population
Serotype 3 at Year 1:S0.0
Serotype 12 at Year 1:S5.6
Serotype 15A at Year 1:S0.0
Serotype 15B at Year 1:S5.6
Serotype 15F at Year 1:S0.0
Serotype 19A at Year 1:S5.6
Serotype 19F at Year 1:S5.6
Serotype 21 at Year 1:S0.0
Serotype 22F at Year 1:S11.1
Serotype 23A at Year 1:S5.6
Serotype 38 at Year 1:S5.6
Serotype 3 at Year 2:S28.6
Serotype 12 at Year 2:S0.0
Serotype 15A at Year 2:S0.0
Serotype 15B at Year 2:S0.0
Serotype 15F at Year 2:S0.0
Serotype 19A at Year 2:S28.6
Serotype 19F at Year 2:S0.0
Serotype 21 at Year 2:S0.0
Serotype 22F at Year 2:S0.0
Serotype 23A at Year 2:S0.0
Serotype 38 at Year 2:S0.0
Serotype 3 at Year 3:S33.3
Serotype 12 at Year 3:S0.0
Serotype 15A at Year 3:S0.0
Serotype 15B at Year 3:S0.0
Serotype 15F at Year 3:S0.0
Serotype 19A at Year 3:S0.0
Serotype 19F at Year 3:S0.0
Serotype 21 at Year 3:S0.0
Serotype 22F at Year 3:S0.0
Serotype 23A at Year 3:S0.0
Serotype 38 at Year 3:S0.0
Serotype 3 at Year 1:I0.0
Serotype 12 at Year 1:I0.0
Serotype 15A at Year 1:I0.0
Serotype 15B at Year 1:I0.0
Serotype 15F at Year 1:I0.0
Serotype 19A at Year 1:I5.6
Serotype 19F at Year 1:I0.0
Serotype 21 at Year 1:I0.0
Serotype 22F at Year 1:I0.0
Serotype 23A at Year 1:I0.0
Serotype 38 at Year 1:I0.0
Serotype 3 at Year 2:I0.0
Serotype 12 at Year 2:I0.0
Serotype 15A at Year 2:I0.0
Serotype 15B at Year 2:I0.0
Serotype 15F at Year 2:I0.0
Serotype 19A at Year 2:I14.3
Serotype 19F at Year 2:I0.0
Serotype 21 at Year 2:I0.0
Serotype 22F at Year 2:I0.0
Serotype 23A at Year 2:I0.0
Serotype 38 at Year 2:I0.0
Serotype 3 at Year 3:I0.0
Serotype 12 at Year 3:I0.0
Serotype 15A at Year 3:I0.0
Serotype 15B at Year 3:I0.0
Serotype 15F at Year 3:I0.0
Serotype 19A at Year 3:I0.0
Serotype 19F at Year 3:I11.1
Serotype 21 at Year 3:I0.0
Serotype 22F at Year 3:I0.0
Serotype 23A at Year 3:I0.0
Serotype 38 at Year 3:I0.0
Serotype 3 at Year 1:R0.0
Serotype 12 at Year 1:R0.0
Serotype 15A at Year 1:R5.6
Serotype 15B at Year 1:R0.0
Serotype 15F at Year 1:R0.0
Serotype 19A at Year 1:R22.2
Serotype 19F at Year 1:R0.0
Serotype 21 at Year 1:R0.0
Serotype 22F at Year 1:R0.0
Serotype 23A at Year 1:R0.0
Serotype 38 at Year 1:R0.0
Serotype 3 at Year 2:R0.0
Serotype 12 at Year 2:R0.0
Serotype 15A at Year 2:R0.0
Serotype 15B at Year 2:R0.0
Serotype 15F at Year 2:R0.0
Serotype 19A at Year 2:R28.6
Serotype 19F at Year 2:R0.0
Serotype 21 at Year 2:R0.0
Serotype 22F at Year 2:R0.0
Serotype 23A at Year 2:R0.0
Serotype 38 at Year 2:R0.0
Serotype 3 at Year 3:R11.1
Serotype 12 at Year 3:R0.0
Serotype 15A at Year 3:R0.0
Serotype 15B at Year 3:R0.0
Serotype 15F at Year 3:R0.0
Serotype 19A at Year 3:R11.1
Serotype 19F at Year 3:R0.0
Serotype 21 at Year 3:R0.0
Serotype 22F at Year 3:R0.0
Serotype 23A at Year 3:R0.0
Serotype 38 at Year 3:R0.0
SecondaryAntimicrobial Susceptibility of Streptococcus Pneumoniae Isolates for Penicillin: Mastoid Population

Antimicrobial susceptibility of S pneumoniae isolates for penicillin from mastoid samples was categorized as resistant, susceptible or intermediate based on MIC for each serotype at each year of the whole surveillance period. The percentage of S pneumoniae serotypes included 3, 12, 15A, 15B, 15F, 19A, 19F, 21, 22F, 23A, 38, which were to be computed along with exact 2-sided 95% CI based on the observed proportion of isolates. 'Number of isolates analyzed' signifies total number of isolates that were evaluable for this OM.

Time frame:
Surveillance Year 1, 2, 3
Reported as:
Number · percentage of isolates
Antimicrobial Susceptibility of Streptococcus Pneumoniae Isolates for Penicillin: Mastoid Population
percentage of isolatesMastoid Population
Serotype 3 at Year 1:S0.0
Serotype 12 at Year 1:S5.6
Serotype 15A at Year 1:S0.0
Serotype 15B at Year 1:S5.6
Serotype 15F at Year 1:S0.0
Serotype 19A at Year 1:S5.6
Serotype 19F at Year 1:S5.6
Serotype 21 at Year 1:S0.0
Serotype 22F at Year 1:S11.1
Serotype 23A at Year 1:S5.6
Serotype 38 at Year 1:S5.6
Serotype 3 at Year 2:S28.6
Serotype 12 at Year 2:S0.0
Serotype 15A at Year 2:S0.0
Serotype 15B at Year 2:S0.0
Serotype 15F at Year 2:S0.0
Serotype 19A at Year 2:S14.3
Serotype 19F at Year 2:S0.0
Serotype 21 at Year 2:S0.0
Serotype 22F at Year 2:S0.0
Serotype 23A at Year 2:S0.0
Serotype 38 at Year 2:S0.0
Serotype 3 at Year 3:S44.4
Serotype 12 at Year 3:S0.0
Serotype 15A at Year 3:S0.0
Serotype 15B at Year 3:S0.0
Serotype 15F at Year 3:S0.0
Serotype 19A at Year 3:S0.0
Serotype 19F at Year 3:S0.0
Serotype 21 at Year 3:S0.0
Serotype 22F at Year 3:S11.1
Serotype 23A at Year 3:S0.0
Serotype 38 at Year 3:S0.0
Serotype 3 at Year 1:I0.0
Serotype 12 at Year 1:I0.0
Serotype 15A at Year 1:I0.0
Serotype 15B at Year 1:I0.0
Serotype 15F at Year 1:I0.0
Serotype 19A at Year 1:I0.0
Serotype 19F at Year 1:I0.0
Serotype 21 at Year 1:I0.0
Serotype 22F at Year 1:I0.0
Serotype 23A at Year 1:I0.0
Serotype 38 at Year 1:I0.0
Serotype 3 at Year 2:I0.0
Serotype 12 at Year 2:I0.0
Serotype 15A at Year 2:I0.0
Serotype 15B at Year 2:I0.0
Serotype 15F at Year 2:I0.0
Serotype 19A at Year 2:I0.0
Serotype 19F at Year 2:I0.0
Serotype 21 at Year 2:I0.0
Serotype 22F at Year 2:I0.0
Serotype 23A at Year 2:I0.0
Serotype 38 at Year 2:I0.0
Serotype 3 at Year 3:I0.0
Serotype 12 at Year 3:I0.0
Serotype 15A at Year 3:I0.0
Serotype 15B at Year 3:I0.0
Serotype 15F at Year 3:I0.0
Serotype 19A at Year 3:I0.0
Serotype 19F at Year 3:I0.0
Serotype 21 at Year 3:I0.0
Serotype 22F at Year 3:I0.0
Serotype 23A at Year 3:I0.0
Serotype 38 at Year 3:I0.0
Serotype 3 at Year 1:R0.0
Serotype 12 at Year 1:R0.0
Serotype 15A at Year 1:R5.6
Serotype 15B at Year 1:R0.0
Serotype 15F at Year 1:R0.0
Serotype 19A at Year 1:R33.3
Serotype 19F at Year 1:R5.6
Serotype 21 at Year 1:R0.0
Serotype 22F at Year 1:R0.0
Serotype 23A at Year 1:R0.0
Serotype 38 at Year 1:R0.0
Serotype 3 at Year 2:R0.0
Serotype 12 at Year 2:R0.0
Serotype 15A at Year 2:R0.0
Serotype 15B at Year 2:R0.0
Serotype 15F at Year 2:R0.0
Serotype 19A at Year 2:R57.1
Serotype 19F at Year 2:R0.0
Serotype 21 at Year 2:R0.0
Serotype 22F at Year 2:R0.0
Serotype 23A at Year 2:R0.0
Serotype 38 at Year 2:R0.0
Serotype 3 at Year 3:R0.0
Serotype 12 at Year 3:R0.0
Serotype 15A at Year 3:R0.0
Serotype 15B at Year 3:R0.0
Serotype 15F at Year 3:R0.0
Serotype 19A at Year 3:R11.1
Serotype 19F at Year 3:R11.1
Serotype 21 at Year 3:R0.0
Serotype 22F at Year 3:R0.0
Serotype 23A at Year 3:R0.0
Serotype 38 at Year 3:R0.0
SecondaryAntimicrobial Susceptibility of Streptococcus Pneumoniae Isolates for Trimethoprim/Sulfamethoxazole (TMP/S): Mastoid Population

Antimicrobial susceptibility of S pneumoniae isolates for TMP/S from mastoid samples was categorized as resistant, susceptible or intermediate based on MIC for each serotype at each year of the whole surveillance period. The percentage of S pneumoniae serotypes included 3, 12, 15A, 15B, 15F, 19A, 19F, 21, 22F, 23A, 38, which were to be computed along with exact 2-sided 95% CI based on the observed proportion of isolates. 'Number of isolates analyzed' signifies total number of isolates that were evaluable for this OM.

Time frame:
Surveillance Year 1, 2, 3
Reported as:
Number · percentage of isolates
Antimicrobial Susceptibility of Streptococcus Pneumoniae Isolates for Trimethoprim/Sulfamethoxazole (TMP/S): Mastoid Population
percentage of isolatesMastoid Population
Serotype 3 at Year 1:S0.0
Serotype 12 at Year 1:S0.0
Serotype 15A at Year 1:S0.0
Serotype 15B at Year 1:S0.0
Serotype 15F at Year 1:S0.0
Serotype 19A at Year 1:S0.0
Serotype 19F at Year 1:S5.6
Serotype 21 at Year 1:S0.0
Serotype 22F at Year 1:S5.6
Serotype 23A at Year 1:S0.0
Serotype 38 at Year 1:S0.0
Serotype 3 at Year 2:S0.0
Serotype 12 at Year 2:S0.0
Serotype 15A at Year 2:S0.0
Serotype 15B at Year 2:S0.0
Serotype 15F at Year 2:S0.0
Serotype 19A at Year 2:S0.0
Serotype 19F at Year 2:S0.0
Serotype 21 at Year 2:S0.0
Serotype 22F at Year 2:S0.0
Serotype 23A at Year 2:S0.0
Serotype 38 at Year 2:S0.0
Serotype 3 at Year 3:S33.3
Serotype 12 at Year 3:S0.0
Serotype 15A at Year 3:S0.0
Serotype 15B at Year 3:S0.0
Serotype 15F at Year 3:S0.0
Serotype 19A at Year 3:S0.0
Serotype 19F at Year 3:S0.0
Serotype 21 at Year 3:S0.0
Serotype 22F at Year 3:S0.0
Serotype 23A at Year 3:S0.0
Serotype 38 at Year 3:S0.0
Serotype 3 at Year 1:I0.0
Serotype 12 at Year 1:I0.0
Serotype 15A at Year 1:I0.0
Serotype 15B at Year 1:I0.0
Serotype 15F at Year 1:I0.0
Serotype 19A at Year 1:I5.6
Serotype 19F at Year 1:I0.0
Serotype 21 at Year 1:I0.0
Serotype 22F at Year 1:I0.0
Serotype 23A at Year 1:I0.0
Serotype 38 at Year 1:I0.0
Serotype 3 at Year 2:I0.0
Serotype 12 at Year 2:I0.0
Serotype 15A at Year 2:I0.0
Serotype 15B at Year 2:I0.0
Serotype 15F at Year 2:I0.0
Serotype 19A at Year 2:I28.6
Serotype 19F at Year 2:I0.0
Serotype 21 at Year 2:I0.0
Serotype 22F at Year 2:I0.0
Serotype 23A at Year 2:I0.0
Serotype 38 at Year 2:I0.0
Serotype 3 at Year 3:I0.0
Serotype 12 at Year 3:I0.0
Serotype 15A at Year 3:I0.0
Serotype 15B at Year 3:I0.0
Serotype 15F at Year 3:I0.0
Serotype 19A at Year 3:I0.0
Serotype 19F at Year 3:I11.1
Serotype 21 at Year 3:I0.0
Serotype 22F at Year 3:I0.0
Serotype 23A at Year 3:I0.0
Serotype 38 at Year 3:I0.0
Serotype 3 at Year 1:R0.0
Serotype 12 at Year 1:R5.6
Serotype 15A at Year 1:R0.0
Serotype 15B at Year 1:R5.6
Serotype 15F at Year 1:R0.0
Serotype 19A at Year 1:R22.2
Serotype 19F at Year 1:R5.6
Serotype 21 at Year 1:R0.0
Serotype 22F at Year 1:R5.6
Serotype 23A at Year 1:R5.6
Serotype 38 at Year 1:R5.6
Serotype 3 at Year 2:R28.6
Serotype 12 at Year 2:R0.0
Serotype 15A at Year 2:R0.0
Serotype 15B at Year 2:R0.0
Serotype 15F at Year 2:R0.0
Serotype 19A at Year 2:R42.9
Serotype 19F at Year 2:R0.0
Serotype 21 at Year 2:R0.0
Serotype 22F at Year 2:R0.0
Serotype 23A at Year 2:R0.0
Serotype 38 at Year 2:R0.0
Serotype 3 at Year 3:R11.1
Serotype 12 at Year 3:R0.0
Serotype 15A at Year 3:R0.0
Serotype 15B at Year 3:R0.0
Serotype 15F at Year 3:R0.0
Serotype 19A at Year 3:R11.1
Serotype 19F at Year 3:R0.0
Serotype 21 at Year 3:R0.0
Serotype 22F at Year 3:R0.0
Serotype 23A at Year 3:R0.0
Serotype 38 at Year 3:R0.0
SecondaryPercentage of Participants With Primary Clinical Diagnosis of Otitis Media

Percentage of participants with primary diagnosis of otitis media was computed along with exact 2-sided 95% CI based on the observed proportion of participants for each of the 3 surveillance year. Results for baseline period were analyzed for participants who received routinely recommended vaccination of 13vPnC. The cases of otitis media reported during the baseline period were captured by the Texas Children's Hospital, which was the only site that collected this information during the baseline period. Percentage of participants was calculated by dividing number of participants with at least 1 MEF sample for the specified year by total number of participants with at least 1 MEF sample for the 3 year surveillance period.

Time frame:
Baseline Year 1, 2, 3; Surveillance Year 1, 2, 3
Reported as:
Number · percentage of participants
Percentage of Participants With Primary Clinical Diagnosis of Otitis Media
percentage of participantsMEF Population
Baseline Year 1: 200724.0 (14.9 to 35.3)
Baseline Year 2: 200845.3 (33.8 to 57.3)
Baseline Year 3: 200930.7 (20.5 to 42.4)
Surveillance Year 1: 201137.8 (32.8 to 43.1)
Surveillance Year 2: 201231.1 (26.3 to 36.2)
Surveillance Year 3: 201331.1 (26.3 to 36.2)
SecondaryPercentage of Participants With Primary Clinical Diagnosis of Mastoiditis

Percentage of participants with primary diagnosis of mastoiditis was computed along with exact 2-sided 95% CI based on the observed proportion of participants for each of the 3 surveillance year. Percentage of participants was calculated by dividing number of participants with at least 1 mastoid sample for the specified year by total number of participants with at least 1 mastoid sample for the 3 year surveillance period.

Time frame:
Surveillance Year 1, 2, 3
Reported as:
Number · percentage of participants
Percentage of Participants With Primary Clinical Diagnosis of Mastoiditis
percentage of participantsMastoid Population
Surveillance Year 152.9 (35.1 to 70.2)
Surveillance Year 220.6 (8.7 to 37.9)
Surveillance Year 326.5 (12.9 to 44.4)

Adverse events

Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
MEF Population———
Mastoid Population———

Baseline characteristics

All participants from whom microbiologic specimen of S pneumoniae isolates from MEF or mastoiditis sample were obtained during surveillance period.

Age, Continuous
Age, Continuous(months)MEF PopulationMastoid PopulationTotal
Mean28.7 ± 26.035.5 ± 47.229.3 ± 28.5
Sex/Gender, Customized
Sex/Gender, Customized(Participants)MEF PopulationMastoid PopulationTotal
Female14418162
Male20916225
Not collected404
08

Study locations

8 sites
  • Arkansas Children's Hospital
    Little Rock, Arkansas 72202, United States
  • Children's Hospital of Los Angeles - University of Southern California School of Medicine
    Los Angeles, California 90027, United States
  • Rady Children's Hospital
    San Diego, California 92123, United States
  • Children's Memorial Hospital- Feinberg School Medicine, Northwestern University
    Chicago, Illinois 60614, United States
  • Brenner Children's Hospital - Wake Forest University School of Medicine
    Winston-Salem, North Carolina 27157, United States
  • Nationwide Children's Hospital - Ohio State University of Medicine and Public Health
    Columbus, Ohio 43205, United States
  • Children's Hospital of Pittsburgh - University of Pittsburgh Medical Center
    Pittsburgh, Pennsylvania 15224, United States
  • Texas Children's Hospital
    Houston, Texas 77030, United States
09

References and documents

Individual participant data

Plan to share: No — Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from May 2010 to primary completion in Dec 2013, 42 months.

Results were first posted in Nov 2020, 6 years 10 months after primary completion.

Of 22 observational studies under Otitis Media, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 67. This study's 42 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 8, 2010
First posted
Jan 10, 2011
StartActual
May 21, 2010
Primary completionActual
Dec 19, 2013
CompletionActual
Dec 19, 2013
Results first posted
Nov 10, 2020
Last update
May 23, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 23, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01272999
Lead sponsor
Pfizer
Responsible party
Sponsor
First posted
Jan 10, 2011
Start date
May 21, 2010
Primary completion
Dec 19, 2013
Completion
Dec 19, 2013
Results posted
Nov 10, 2020
Last update
May 23, 2023

Study contacts

Pfizer CT.gov Call Center
study director · Pfizer

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion